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Abstract of the Dissertation
Understanding Huntington’s Disease using Machine Learning
Approaches
By
Sonali Jayant Lokhande
Keck Graduate Institute of Applied Life Sciences: 2017
Huntington’s disease (HD) is a debilitating neurodegenerative disorder with a
complex pathophysiology. Despite extensive studies to study the disease, the
sequence of events through which mutant Huntingtin (mHtt) protein executes its
action still remains elusive. The phenotype of HD is an outcome of numerous
processes initiated by the mHtt protein along with other proteins that act as either
suppressors or enhancers of the effects of mHtt protein and PolyQ aggregates.
Utilizing an integrative systems biology approach, I construct and analyze a
Huntington’s disease integrome using human orthologs of protein interactors of
wild type and mHtt protein. Analysis of this integrome using unsupervised machine
learning methods reveals a novel connection linking mHtt protein with
chromosome condensation and DNA repair. I generate a list of candidate genes that
upon validation in a yeast and drosophila model of HD are shown to affect the mHtt

phenotype and provide an in-vivo evidence of our hypothesis. A separate supervised
machine learning approach is applied to build a classifier model that predicts
protein interactors of wild type and mHtt protein. Both the machine learning models
that I employ, have important applications for Huntington’s disease in predicting
both protein and genetic interactions of huntingtin protein and can be easily
extended to other PolyQ and neurodegenerative disorders such as Alzheimer’s and
Parkinson’s disease.
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Chapter 1
1 Huntington’s disease and its links to chromatin
condensation mechanisms
1.1 Introduction:
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder
caused by the expansion of CAG triplet repeats in the first exon of the Huntingtin
(HTT) gene. Despite this apparently simple genetic basis, identified nearly three
decades ago, the molecular pathophysiology of this inherited disorder that affects a
significant number of people in the prime of their youth remains intractable, and
with limited treatment options beyond managing the symptoms. This review
summarizes the genetic basis of HD, lists the genetic models currently in use to
study its molecular pathology, and critically examines the involvement of
mitochondrial dysfunction, DNA damage repair pathways, and chromatin
dynamics in HD progression. Specifically, this review summarizes recent studies
that indicate a role for chromosome condensation defects, especially at the
ribosomal DNA (rDNA), in molecular pathogenesis of HD. We hope to stimulate
interest of HD researchers in further examining the novel associations among these
apparently disparate cellular processes.
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2

1.2 The Genetic Basis
The HTT gene encodes an expanded polyglutamine stretch in the huntingtin (Htt)
protein. Despite being inherited in an autosomal dominant manner, the prevalence
of this disease varies from just 5 to 6 per 100,000 people in North America, Europe
and Australia with an incidence of 0.38 per 100,000 year.(Pringsheim et al., 2012)
HD has been classified as a ‘rare’ or ‘orphan disease’. The low level of occurrence
of HD can be explained by reduced penetrance of mutant HTT alleles in individuals
with 36-39 copies of CAG repeats.(Huntington Study Group COHORT
Investigators and Dorsey, 2012; McNeil et al., 1997; Panegyres and Goh, 2011;
Quarrell et al., 2007; Sequeiros et al., 2010) Moreover, inheriting a contracted CAG
repeat (36-39 copies) from its parent could reduce the risk of the individual
developing the disease.(Nahhas et al., 2009) On average, the age of disease onset
is inversely correlated with the number of CAG repeats; however, the repeat
number explains approximately 50-70 % of the age of onset data. The remaining
variability in age of onset is attributed to various genetic and environmental factors
that act in conjunction with the HTT gene.(Djoussé et al., 2003; Project* and
Wexler, 2004) Individuals with shorter CAG repeats exhibit a gradual decline in
clinical progression than individuals with larger CAG repeats. Hence CAG repeat
length is an important determinant of clinical progression of HD. This suggests that
aging itself might influence clinical outcomes in Huntington's disease.(Rosenblatt
et al., 2012) A peculiar observation is that the expanded HTT allele when inherited

3

through the male germ line, often leads to a more severe clinical course than when
inherited through the female germ line. Children of HD sufferers experience HD
symptoms 8 years earlier than that of their respective fathers.(Ranen et al., 1995)
These observations suggest that the CAG expansion rate might be higher in the
male germline(Duyao et al., 1993), the possibility of imprinting, which might affect
the expression of genes involved in molecular pathogenesis(Farrer et al., 1992;
Reik, 1988; Ridley et al., 1991), or a combination of these two factors.
The HD phenotype is a product of various aberrant genetic and epigenetic
mechanisms triggered by the mutant HTT allele (which are reviewed in detail in the
article by Valor Guiretti et al)(Valor and Guiretti, 2014) and also through various
other proteins that are either suppressors or enhancers of the mutant Htt (mHtt)
protein and the PolyQ aggregates. Quantitative interaction proteomic studies
identify proteins interacting with both wild-type and mHtt protein.(Culver et al.,
2012; Hosp et al., 2015; Ratovitski et al., 2012; Shirasaki et al., 2012) Conclusions
from quantitative proteomics have been validated by suppressor/enhancer studies
on a model organism (fly). Potential evidences of candidate gene involvement have
been verified by the presence of SNPs within candidate human genes in patients. 20
The study of transcriptional dysfunction in HD through GWAS has enabled the
charting of various genomic loci of Htt interacting proteins such as REST, PGC1alpha, HSF1, and Foxp1(Lucas et al., 2012; Riva et al., 2012; Strand et al., 2007;
Valor, 2014) and the Htt protein itself.(Benn et al., 2008) A combination of Genome

4

wide correlation of histone acetylation(McFarland et al., 2012) and gene expression
defects in a HD mouse models identified aberrant deacetylation of H3K9/14ac and
H4K12ac(McFarland et al., 2012) along with transcriptional dysregulation of other
Htt interacting proteins.(Valor et al., 2013)

1.3 Clinical Presentation
Clinical presentation of HD has been observed to occur in individuals at any time
between the ages of 1 and 80. The symptomatic phase of the disease (Table 1) is
preceded by a prediagnostic phase in which patients show subtle changes in
cognition and motor control, which mostly go unnoticed.(Walker, 2007) The
prediagnostic phase leads to the diagnostic phase in which patients begin showing
distinct chorea, motor incoordination and impersistence along with slow saccadic
eye movements.(Watts and Koller, 1997; Weiner and Lang, 1989) Cognitive
dysfunction affects executive functions and delays new motor skills(Craufurd and
Snowden, 2002), which worsens with time (Figure 1.1). Depression and suicidal
behavior are common, along with symptoms of psychosis and mania.(Walker,
2007) A question remains as to whether early cognitive dysfunction can be
correlated with CAG repeat length in HD patients. A recent study using Functional
Magnetic Resonance Imaging (fMRI) and structural-MRI, indicated that there is a
significant correlation between executive function performance levels with disease

5

progression. No studies have been reported to our knowledge that explores
cognitive dysfunction as a correlate of CAG repeat length.

Diagnosis of HD is usually definite when typical clinical symptoms start to develop
coupled with a positive family history. However, in other patients, and those with
early onset of the disease, the symptoms might resemble other disorders like the
dentatorubropallidoluysian atrophy (DRPLA), Huntington’s disease-like 2(HDL2)
and Spinocerebellar ataxia (SCA).(Margolis et al., 2004; T et al., 1985; Toyoshima
et al., 2004; Walker, 2007)
Routine CET and MRI scans help assess the severity and progress of HD but both
are usually not useful for early diagnosis of the disease. PET and functional MRI
scans can show atrophy of the caudate nucleus and the putamen almost 9-11 years
earlier than the disease onset.(Aylward et al., 2004; Künig et al., 2000; Lawrence
et al., 1998; Paulsen et al., 2004; Rosas et al., 2003) The PREDICT-HD study in
2008, also found striatal volume to be the strongest biomarker predicting the onset
of disease when related to CAG repeat length.(Paulsen et al., 2008)
Genetic testing of HD patients and their families is a definitive diagnostic method
that confirms the presence of the disease. These genetic tests can be administered
as a predictive, pre-natal or a diagnostic assay depending on how the patient
presents clinically. However, the uptake of the test has been minimal considering
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the paucity of effective treatment(Laccone et al., 1999) and comes with its own set
of ethical and psychosocial challenges that need to be addressed before and after
the test has been conducted.(Tassicker et al., 2006)
Almost all treatment options currently available for the disease are symptomatic,
and focus on addressing motor symptoms such as chorea and dystonia. Absence of
reliable diagnostic biomarkers for early stages of the disease, and a lack of curative
strategies call for further research in understanding this complex neurological
disorder. Cell and various animal models have therefore been developed to better
explain the molecular mechanisms underlying HD. While cell models help clarify
the central apparatus of the disease, animal models help in recreating the HD
genotype and phenotype to screen for therapeutic compounds and targets. The next
section will discuss more about the currently available cell and animal models in
HD.

1.4 Cell/Animal Models for HD.
Several in vitro and in vivo genetic models developed for HD (summarized in Table
2), help in elucidating and dissecting various molecular pathways affected in this
disease.
Cell lines and primary cultures such as the human embryonic kidney (HEK293T)
cell line, are effective instruments in understanding the basic molecular processes
contributing to neural degeneration and death.(Cisbani and Cicchetti, 2012)
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Inducible cell systems on the other hand help experimentally modulate and allow
assessment of the spatial and temporal activation of genes and proteins. Such
systems therefore are useful for studying effects of gene and protein expression in
a diseased state. In vitro models have been useful to characterize the cleavage
mechanism of mHtt protein(Johri and Beal, 2010; Kim et al., 2001; Miller et al.,
2010), and the factors influencing the process(Johri and Beal, 2010; Martindale et
al., 1998), and how polyQ aggregates lead to cell death in HD.(Wyttenbach et al.,
2001; Zala et al., 2005)
Yeast models of HD have helped identify genes that modify mHtt toxicity and
helped provide targets for validation in higher organisms. For example, a high
throughput screening assay in yeast HD model (Htt-103Q) identified a small
molecule inhibitor (C2-8) of polyQ aggregation which was validated in a
Drosophila HD model to show suppression of neurodegeneration.(Zhang et al.,
2005) A proof-of-concept study carried out in R6/2 mouse model of HD showed
that mice treated with C2-8 improved motor performance and reduced neuronal
atrophy with smaller huntingtin aggregates.(Chopra et al., 2007) A follow-up
preclinical study of C2-8 in R6/2 also found evidence supporting its role in reducing
the size of mHtt aggregates but did not find a significant role in improving
behavioral deficits in this mouse model of HD.(Wang et al., 2013)
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In vivo models of HD include organisms such as Caenorhabditis elegans (C.
elegans), Drosophila melanogaster, mice and rats. C. elegans models are mostly
generated by expression of N-terminal fragments of mHtt, ranging from 57 to 171
amino acids. Transgenic expression of mHtt in C. elegans can result in agedependent

mechanosensory

defects,

neuronal

dysfunction

and

neurodegeneration.(Faber et al., 1999; Parker et al., 2001)
Drosophila models of HD mostly use an inducible gene expression system, UASGAL4, to express full-length or N-terminal Htt fragments ranging from 65 to 548
amino acids of the expanded repeat mutant genes. Such models recapitulate a
progressive neurodegeneration phenotype of HD along with motor dysfunction and
reduced survival.(Marsh et al., 2003; Robinow and White, 1988)
Transgenic mouse models for HD express N-terminal fragments of human HTT of
various sizes. R6/1 and R6/2 mice express exon 1 of human HTT with 116 and 144
CAG repeats respectively and show somatic instability of the CAG repeat
tract.(Mangiarini et al., 1996) Truncated N-terminal mouse models exhibit an
accelerated degenerative phenotype including motor, cognitive and behavioral
aberrations along with increased mortality.(Schilling et al., 1999)
Knock-in mouse models are created by inserting an extended CAG tract with CAG
repeat sizes ranging from 50 to 200 into an endogenous mouse HTT
gene.(Dougherty et al., 2013; Heng et al., 2007; Lin et al., 2001; Menalled et al.,
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2002, 2003; Wheeler et al., 2002; White et al., 1997) Out of the many such knockin mouse models, CAG140 (119/140 CAG repeats), the HdhQ111 (111 CAG
repeats), and HdhQ150 (150 CAG repeats)

mice are the most genetically

appropriate to HD in terms of expression of mHtt(Pouladi et al., 2013) and their
ability to generate neurological and neurodegenerative symptoms.(Hickey et al.,
2008; Lerner et al., 2012; Menalled et al., 2003; Wheeler et al., 2002)
Some transgenic models such as the BACHD (97 CAG repeats) and YAC128 (128
CAG repeats) mice express the entire mutant HTT gene and show a comparatively
milder and more progressive phenotype with cognitive disturbances along with
striatal and cortical atrophy.(Ehrnhoefer et al., 2009; Gray et al., 2008; Raamsdonk,
2005)

1.5 Classical Views of Molecular Pathogenesis in HD
The mutant HTT gene confers a toxic gain of function and leads to protein
misfolding and aggregation.(Duyao et al., 1995; Mangiarini et al., 1996; Nasir et
al., 1995; Zeitlin et al., 1995) The toxic gain of function by the mutant HTT gene
may be due to the short N-terminal fragments of mHtt protein produced through
cleavage by various proteases.(Bizat et al., 2003; Cowan and Raymond, 2006;
Gafni and Ellerby, 2002; Gafni et al., 2004; Goffredo et al., 2002; Graham et al.,
2006; Kim et al., 2001; Lee and Kim, 2006; Wellington et al., 1998) Reduction in
caspase 6 –dependent cleavage of full length mHtt significantly slows the
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progression of neurodegeneration in YAC mouse model for HD.(Graham et al.,
2006) Additional studies in neurons and mice models implicate that even a loss of
potentially beneficial function of wild-type Htt contribute to HD disease
phenotype.(Cattaneo et al., 2001; Faber et al., 1998; Hackam et al., 2000; Kalchman
et al., 1997) Though, wild-type Htt is known to up-regulate of BDNF (Brainderived neurotrophic factor) transcription gene, its function is lost in the cortex of
YAC72

HD

mice

underlining

the

concept

of

loss

of Htt-mediated

function(Cattaneo et al., 2001) (Figure 1.2). Despite extensive experimental studies
carried out in both gene knock-out and gene knock-in HD models, the multifaceted
functions of the normal Htt protein or that of the mHtt protein remain elusive. The
mHtt protein is known to physically interact with numerous other proteins, some of
which do or do not interact with the wild-type Htt protein. The complexity of the
molecular patho-physiology arises largely because of the proclivity and
promiscuity of these interactions. Some of the interaction partners are involved in
vesicle transport and gene transcription functions. These and many other functions
are associated with the energy producing apparatus of the cell, such as the
endoplasmic reticulum (ER) and mitochondria.
Studies with knock-in HD mouse model (homozygous for mHtt-Q111) showed that
mHtt is associated directly with the outer mitochondrial membrane, and increases
its susceptibility to calcium-induced permeability transition leading to cytochrome
C release and apoptosis.(Choo et al., 2004; Panov et al., 2002; Petrasch-Parwez et
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al., 2007) Furthermore, it has been suggested that the accumulation of abnormal
misfolded proteins in the cells expressing mHtt protein overwhelms the ER
apparatus responsible for quality control of proteins, which causes ER stress and
trigger cell death.(Rao and Bredesen, 2004)

1.6 Mitochondrial dysfunction and oxidative stress in HD
The association of mHtt with mitochondria occurs both directly and indirectly and
has been studied extensively over the past years. A decrease in the mitochondrial
membrane potential due to a rise in proton conductivity(Panov et al., 2005; Sawa
et al., 1999) and the opening of the mitochondrial permeability transition (MPT)
pore (Choo et al., 2004), are a few well known mechanisms through which the mHtt
protein affects mitochondrial function directly. Biochemical analysis of R6/2
mouse striatum demonstrate deficits in mitochondrial complex IV and aconitase
activities, along with decrease in complex I/II and IV. (Hausladen and Fridovich,
1994; Tabrizi et al., 1999, 2000) Mitochondria in cells expressing mHtt are thus
particularly susceptible to oxidative stress and cell death. Inhibition of the
mitochondrial respiratory chain leads to increased production of reactive oxygen
species (ROS), such as the superoxide (O2•-) radical, hydrogen peroxide (H2O2) and
peroxynitrite (ONOO -), followed by fall in ATP levels.
Mitochondrial trafficking is indirectly affected by mHtt due to sequestration of
trafficking components that are required for efficient axonal transport.(Trushina et
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al., 2004) Specific N-terminal mHtt fragments accumulate as aggregates and
physically block the movement of mitochondria within neurons(Chang et al., 2006;
Orr et al., 2008) and also affect the mobility of Mitochondria trapped in the vicinity
of the mHtt aggregates.(Chang et al., 2006) Fragmented mitochondria are a
significant feature of HD cells, and exhibit alterations in cristae structure reflecting
a disruption of electronic transport mechanisms(Solans et al., 2006), release of
cytochrome C and eventual destruction of mitochondria(Costa et al., 2010) (Figure
1.2). Readers are referred to some excellent reviews on this subject(Chakraborty et
al., 2014; Damiano et al., 2010; Johri et al., 2013) for detailed information.

1.7 A possible mechanism behind the gradual onset of mHtt
toxicity
It appears reasonable to postulate that the gradual onset of the severity of HD
phenotype is related to a cumulative process that is proportional to the polyQ repeat
length as well as time during which the toxicity of polyQ is expressed. We here
examine the evidences that point to several such cumulative processes in cellular
physiology, which are thought to be affected by proteins containing polyQ tracts,
especially by the pathogenic mHtt proteins.
Pathogenic polyQ repeats similar to those produced by the expanded CAG repeats
in mutant HTT genes have been found to affect several cellular processes through
alteration

of

protein

conformation

causing

aberrant

protein-protein
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interactions,(Schaffar et al., 2004) leading to depletion of tRNA and translational
frameshifting.(Girstmair et al., 2013) Q-rich tandem repeats (TR) are often present
in transcriptional regulators(Gemayel et al., 2010; Legendre et al., 2007), a property
that appears to be evolutionarily conserved.(Schaper et al., 2014) A comparative
genomic study by Gemayel et al carried out in repeat variants of the yeast
transcriptional regulatory protein Ssn6p (Cyc8p) demonstrated that an alteration of
the

repeat

length

leads

to

altered

gene

expression

and

phenotypic

variation.(Gemayel et al., 2015) This study found that targets of Q-rich regulators
exhibit increased gene expression across various time scales. Htt protein appears to
be a transcription factor itself, and variation in its PolyQ length might therefore
cause changes in its transcriptional activity.(Benn et al., 2008) Does altered gene
expression in the presence of mHtt protein gradually lead to neuronal death in
striatal cells? Below we examine the effects of mHtt on specific transcriptional
regulators, which could potentially accumulate over time.
Indirect evidence links mHtt to mitochondrial dysfunction through its interaction
with Tumor Protein 53 (p53). Studies with HD patient lymphoblasts stably
expressing Htt N63-148Q, and in 293T (derivative of human embryonic kidney 293
cells, containing the SV40 T-antigen) cells transfected with a gene encoding the
171 amino acid long N-terminal-fragment of Htt containing either 23 or 148
glutamine repeats (N171-23Q or N171-148Q), respectively, or the full-length (FL)
version of Htt (FL-23Q or FL-82Q) show that the mHtt binds selectively to nuclear
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p53 and stabilizes the latter to increase transcriptional activity of p53 in the
nucleus(Bae et al., 2005) (Figure 1.2). It has also been speculated that the
interaction of mHtt with p53 might interfere with p53’s interaction with its negative
regulator, E3 Ubiquitin Protein Ligase (Mdm2) in the cytoplasm, thus stabilizing
p53 further(Bae et al., 2005) (Figure 1.2). Over-expression of p53 was shown to
increase the expression of various mitochondria-related pro-apoptotic proteins such
as BCL2-Associated X Protein (Bax) and BCL2 Binding Component 3
(BBC3/PUMA) responsible for regulating mitochondrial depolarization and ROS
levels(Bae et al., 2005; Toshiyuki and Reed, 1995; Yu et al., 2001) (Figure 1.2).
Grison et al.(Grison et al., 2011) demonstrated that mHtt expression, which in turn
causes p53 stabilization, leads to increased phosphorylation of p53 on Ser46. This
causes p53 to interact with phosphorylation-dependent prolyl isomerase Pin1, and
induce the expression of pro-apoptotic genes – Bax and PUMA.(Grison et al., 2011)
Other mitochondrial proteins known to be activated by p53 include Protein Noxa
(NOXA) and Tumor Protein P53 Regulated Apoptosis Inducing Protein 1
(P53AIP1), all of which induce apoptosis when overexpressed.(Oda et al., 2000a,
2000b) Considering the above factors, it might be speculated that p53 is in a
hyperactive state in neurons containing the mHtt protein in contrast to its activity
in normal neuronal cells. p53 protein would then be expected to trigger apoptosis
when a threshold level of oxidative damage has occurred in the mitochondria. Until
then, the defective mitochondria may continue to divide and compromise the
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cellular energetics that manifest itself phenotypically through various clinical signs
and symptoms of HD.
The mHtt protein could bring about mitochondrial dysfunction through additional
transcriptional mechanisms not involving p53. mHtt interacts with PPARγ
coactivator-1α (PGC-1α). In addition to playing important roles in glucose
metabolism and adaptive thermogenesis, PGC-1α is also required for the expression
of nuclear respiratory factors such as NRF1 and NRF2(Wu et al., 1999) along with
other mitochondrial genes (e.g., cytochrome C,(Andersson and Scarpulla, 2001)
mitochondrial transcription factor A (mtTFA)(Wu et al., 1999) and respiratory
complexes I-IV.(Kelly and Scarpulla, 2004) PGC-1α is thus an important
transcription factor controlling mitochondrial biogenesis(Wu et al., 1999) and for
the production of mitochondrial –ROS detoxifying enzymes(Kukidome et al.,
2006; St-Pierre et al., 2003; Valle et al., 2005) (Figure 1.2). mHtt inhibits the
transcription of PGC-1α by obstructing the promoter-binding activity of
CREB/TAF4

(cAMP

responsive

element-binding/TATA-binding

protein-

associated factor 4) in mouse striatal cells expressing mHtt 111Q.(Cui et al., 2006)
Indeed, lentivirus mediated overexpression of PGC-1α in the brain striatum of
transgenic (R6/1) mice reverses and rescues the mitochondrial dysfunction as well
as neuronal degeneration.(Cui et al., 2006)
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Taken together, the accumulation of molecular lesions related to defective
transcription factor activity leading to increasing mitochondrial dysfunction can be
reconciled with the observed gradual onset of the severity of neuronal dysfunction
in HD affected brains. These, however, are unlikely to be exclusive mechanisms of
the gradual onset of HD severity. Accumulation of unfolded or misfolded proteins
due to defective chaperone activity in HD neurons may also be a major
contributor.(Chai et al., 1999; Guzhova et al., 2011; Tagawa et al., 2007; Wacker
et al., 2009) Nonetheless, misfolded proteins appear to accumulate in nearly all
cells expressing mHtt while only the striatal neurons appear to be the most
vulnerable and cause the early disease phenotype. This aspect of the disease
mechanism has been reviewed elsewhere.(Cowan and Raymond, 2006)

1.8 Transcriptional regulation, Chromatin dynamics and the role
of SIRT1 in HD.
Recent studies have increasingly highlighted the role of epigenetic mechanisms
involved in chromosome dynamics and cell death in HD. This section will
summarize the most recent findings and will attempt to define future questions and
directions.
Since only certain neuronal cells of the striatal cortex undergo preferential early
death in HD patients whereas mHtt protein is ubiquitously expressed, a major
interest lies in understanding what makes these neuronal cell types more vulnerable
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than others, and how to explain the delayed and progressive effects of mHtt toxicity
on these cells. One rationale for addressing these questions is epigenetics, because
it is the epigenetic modification of the cell’s gene expression states that define celltype specificities. Furthermore, molecular mechanisms of epigenetic processes,
such as DNA methylation levels across genomic landscape are often progressive
and cumulative, thus providing a framework to explain the progressive
accumulation of mHtt toxic effects on the brain. Note also that signals from other
cells, such as input connections from other neurons and their activities(Borrelli et
al., 2008; Meadows et al., 2015; Singh-Taylor et al., 2015), also might affect the
epigenetic states of neurons, thus providing the second rationale framework for the
observation that excitotoxicity is important for susceptibility to mHtt toxicity.(Fan
and Raymond, 2007; Young et al., 1988) Here we approach these problems
primarily through the viewpoint that mHtt’s interaction with mediators of
epigenetic programming might explain both these aspects of HD.
First, we consider possible epigenetic players known to directly interact with mHtt.
Sirtuins (yeast Sir2 homologous proteins) represent a family of epigenetic
regulatory proteins that are highly conserved in evolution from prokaryotes to
higher eukaryotes, including humans(Imai et al., 2000), and at least one member of
this family is known to directly interact with the mHtt protein. There are seven
recognizable Sirtuin genes in human: SIRT1 to SIRT7. The functions of human
SIRT genes are unknown. Based on homology with genes in yeast and other
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organisms, these are thought to be important in epigenetic gene regulation,
chromatin silencing and suppression of recombination within ribosomal DNA
(rDNA) repeats. The encoded proteins have ADP-mono-ribosyltransferase activity.
The seven members of the mammalian Sirtuin family occupy different subcellular
compartments: SIRT6 and SIRT7 are nuclear proteins, SIRT2, SIRT3, and SIRT4 are
located in the mitochondria, while SIRT1 and SIRT5 are found both in the nucleus
and in the mitochondria, and their relative expression levels vary somewhat based
on the cell and tissue type.(Michishita et al., 2005) These proteins are collectively
thought to transduce information on the energetic state of the cell (through sensing
NAD/NADH ratio) to epigenetic processes (through their protein deacetylase
activity).(Imai et al., 2000) Might these functions of Sirtuins be the key to imposing
the specificity of early cell death, mainly the result of excitotoxicity, of striatal
neurons in HD, by dint of a possibly unique metabolic state needed for the normal
survival of these neurons? Sirt1 protein likely functions as a neuroprotective
molecule through several mechanisms via its enzymatic function as a protein
deacetylase on a number of distinct protein substrates. One such well-studied
substrate is the forkhead box O3A (FOXO3a) transcription factor, which is highly
expressed in adult brain.(Kops et al., 2002; Mojsilovic-Petrovic et al., 2009; Peng
et al., 2010) mHtt is known to directly interact with Sirt1 and to inhibit the protein
deacetylase activity of Sirt1, leading to hyperacetylation of Foxo3a (Figure 1.2).
This is correlated with reduced neuronal survival in HD cell models.(Jiang et al.,
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2012) Additional indirect evidence for interaction between mHtt protein and Sirt1
comes from experiments with HEK293 t/17 cells (having partial neuronal
characteristics) containing mHtt (68Q), which showed increased acetylation of p53
–Sirt1 substrate, compared to cells containing wild-type Htt (17Q). This indicates
that mHtt protein might interfere with p53 activity through modulation of Sirt1
deacetylase activity(Jiang et al., 2012) (Figure 1.2). Hyperacetylation of p53 is
directly responsible for triggering DNA damage response of the cell (Figure 1.2).
Similarly, PGC-1alpha is also subject to SIRT1 deacetylase activity.(Nemoto et al.,
2005) Studies on PC12 cells (derived from a transplantable rat pheochromocytoma,
a neuro-endocrine tumor), demonstrated a direct molecular interaction between
SIRT1 and PGC1-alpha causing deacetylation of the latter protein. The resultant
inhibition of transcriptional activity of PGC1-alpha leads to a complex chain of
abnormal downstream interactions which affect both the mitochondrial function
and the respiratory chain complex.(Nemoto et al., 2005) PGC1-alpha is therefore
subject to regulation by various proteins including mHtt and acts in a manner
similar to a master switch that controls mitochondrial function and cellular
respiration. Overexpressed SIRT1 has been shown to attenuate brain atrophy and
improve motor functions in both N-terminal fragment (N171-82Q) and full-length
Htt (BACHD) mice models(Jeong et al., 2012; Jiang et al., 2012) by maintaining
optimal levels of DARPP32 needed for dopamine signaling.(Fienberg et al., 1998;
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Greengard et al., 1999) These studies also demonstrated a neuroprotective effect of
SIRT1 against mHtt induced striatal atrophy.
It is interesting to note that SIRT1 gene overexpression in N171-82Q Huntington
disease mice model also leads to improved glucose tolerance and insulin sensitivity
in these mice along with restoration of normal BDNF levels that are vital for
controlling both glucose metabolism and DARPP32 expression. These findings
suggest a broader metabolic and neuroprotective role of SIRT1 in Huntington’s
disease.(Jiang et al., 2012) In light of the above, mHtt could possibly be one of the
key players connecting the glucose metabolism and neuronal survival pathways
through its interaction with SIRT1—a possibility worthy of further investigations.

1.9 DNA damage and chromatin condensation defects
There is a second pathway in which SIRT1 might be important in HD: through
SIRT1’s role in chromatin condensation. Mice embryos with homozygous null
mutation in SIRT1 gene being to die at E9.5 and no homozygous live animals are
produced. Some mice heterozygous for null SIRT1 mutation exhibit brain
development defects including exencephaly. Complete loss of SIRT1 causes arrest
of cell division in some cells in the early mitotic phase, and the arrested cells exhibit
abnormal chromosome condensation, loss of DNA-damage induced G2/M
checkpoint arrest, aneuploidy, apoptosis, higher frequency of spontaneous DNA
double strand breaks, and the presence of hyper-acetylated lysine-16 (K16) of
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histone H4 and lysine-9 (K9) of histone H3.(Wang et al., 2008) These findings
suggest SIRT1 is important for DNA damage repair in mitotic cells. Given this
function of SIRT1, it is anticipated that mHtt, which inhibits SIRT1 protein
function, should adversely affect DNA-damage repair and cause abnormal
chromatin condensation. Consistently, deficiency of SIRT1 protein (caused by
siRNA) in HEK293T cells cause abnormal loading of histone 1 and the condensin
I protein complex on to the mitotic chromosomes.(Fatoba and Okorokov, 2011)
While it is possible that these findings might indicate higher levels of DNA damage
accumulation in neural cells with depleted SIRT1 activity due to mHtt binding,
these results should be interpreted with caution because condensin I is cytoplasmic,
and its loading on to the chromatin occurs only during mitotic metaphase during
which the nuclear membrane does not exist. Similar adverse effects of SIRT1
depletion on prophase-specific condensin II was not observed in HEK293T cells.
However, SIRT1 is also known to associate with the MRN (MRE11-RAD50NBS1, a protein complex that processes broken DNA) complex.(Tauchi et al.,
2002) A deacetylated NBS1 protein enables the MRN complex in detecting DNA
damage; therefore, hyperacetylation of NBS1 by the inhibition of SIRT1 activity
by mHtt is expected to interfere with DNA damage repair. In fact, hyperacetylated
NBS1 was shown to negatively affect intra-S phase checkpoint of the cell
cycle(Yuan et al., 2007), suggesting that in addition to affecting G2/M DNAdamage checkpoint arrest, the loss of SIRT1 activity might cause increased
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persistence of DNA damage lesions. If the adverse effects of mHtt on DNA damage
repair is indeed relevant for excitotoxicity in striatal neurons, the question of celltype specificity remains unanswered unless one postulates an increased DNA
damage load in cells with high oxidative metabolism due to electrical activities of
this group of neurons. While DNA damage by free radicals are generated by
oxidative metabolism and increased mitochondrial respiration, a clear cause-andeffect relationship between the metabolic state and mHtt mediated cell death has
not yet been established. Measurement of region-specific metabolomes in mouse
brain indicated that no single metabolite but a complex of metabolites (metabolite
signatures)

correlated

well

with the

sensitivity of

brain

regions

to

excitotoxicity.(Jaeger et al., 2015) Specifically, striatal neurons have a unique
metabolite signature. Future studies of region-specific metabolomes of HD mouse
brains, coupled with measurements of intracellular DNA lesions and epigenetic
modification of these regional neurons, should be valuable for understanding how
metabolites might affect neuronal specificity in HD pathogenesis.
Second, we approach the problem from the idea that DNA damage might not be
directly related to the metabolic activity of the striatal neurons, but is the result of
specific neuronal functions. Huntingtin co-localizes with microtubule organizing
bodies, and is thought to facilitate the dynein/dynactin-mediated transport of
organelles including mitochondria along microtubules in neuronal cells(Godin et
al., 2010); siRNA against normal Htt causes mislocalization of p150Glued (subunit
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of dynectin), dynein, and the large nuclear mitotic apparatus (NuMA) protein –
which is essential for microtubule assembly and maintenance.(Radulescu and
Cleveland, 2010) It is possible that mHtt might cause problems with organelle
transport in striatal neurons, which could indirectly influence chromosome
integrity. However, it is hard to see how microtubule malfunction could lead to
DNA damage because neurons do not divide, and therefore microtubule motors are
not expected to be involved in chromosome dynamics in G0-arrested neurons.
Nevertheless, DNA damage might also be directly caused by mHtt interaction with
proteins that modulate chromosome dynamics in a G0 neuron, as discussed in the
next section.

1.10 rDNA condensation defects in HD
Abnormal nucleolar ribosomal DNA (rDNA) condensation, during which
condensin I and II subunits, including Smc2p and Smc4p, are recruited to the rDNA
loci, is related to apoptotic death and DNA damage in mammalian cells(Blank et
al., 2006) (Figure 1.3). Repeat-containing RNA has been demonstrated to associate
with nucleolar protein complexes leading to “nucleolar stress”, which is thought to
trigger cell death through activating the p53 mediated pathway.(Kreiner et al.,
2013) This phenomenon has been shown to be relevant for certain degenerative
disorders of repeat sequences, including HD (Tsoi et al., 2012), ALS and
frontotemporal dementia.(Haeusler et al., 2014) Interestingly, results from our
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laboratory have recently demonstrated that mHtt toxicity in yeast can be suppressed
by several rDNA genes (Chatterjee et al., 2013), most notably by the gene encoding
L12p, a member of the L11p subgroup of ribosomal proteins. More recently it has
been shown that L11p which is recruited to the nucleolus within a poorly-defined
complex associated with repeat-containing noncoding RNA and chromatin
proteins, is directly responsible for triggering apoptosis through activating p53
(Maehama et al., 2014) (Figure 1.3).

An emerging model is that premature or abnormal condensation of the chromatin
at rDNA loci, facilitated by L11p-like proteins and condensins, such as Smc2p,
sequesters an inhibitor of p53 (Mdm2) at the chromatin during S-phase, with the
resulting activation of p53-mediated apoptosis (Figure 1.3). However, there is yet
no direct evidence that mHtt-mediated apoptosis in human cells can be triggered by
abnormal chromatin condensation. Consistent with these is the finding that an RNA
Pol II associated protein UBTF is tri-methylated by ESET, a H3K9 methyl
transferase, and this trimethylation deregulates rDNA condensation in a striatal
Q111 knock-in cell line (relative to Q7 striatal cell line) model of HD(Hwang et al.,
2014) (Figure 1.3). Reduced acetylation of UBTF at K352 by an siRNA against the
CREB protein also reduces rDNA transcription in striatal Q111 expressing neurons
but not in Q7-expressing neurons.(Lee et al., 2011) A genetic evidence connecting

25

rDNA expression with mHtt toxicity comes from recent experiments with the yeast
HD model (chromosomal 103Q N-terminal fragment expressed from GAL
promoter in yeast)(Chatterjee et al., 2013) in which several strong rDNA
suppressors of HD toxicity were discovered. In a genome-wide gain-of-function
suppressor screen for a defect in chromosome condensation by mutation in the
condensin-encoding

gene

smc2,

we

identified

UME1

and

BNA5

as

suppressors.(Patra et al., 2013) UME1 encodes a member of the histone deacetylase
complex, underscoring the importance of epigenetic processes in mHtt toxicity, and
BNA4 and BNA5 encode two successive enzymes in the biosynthesis of NAD from
kynurenine. The latter gene, BNA5, is a current target of HD drug
development.(Beconi et al., 2012; Harris et al., 1998; Santamaría et al., 1996;
Zwilling et al., 2011) The Bna4p enzyme localizes to the mitochondrial outer
membrane, whereas Bna5p localizes both to the nucleus and the cytoplasm (Figure
1.3), suggesting that these two enzymes might form a link between the chromatin,
p53, and mitochondrial abnormality in cells expressing mHtt. These results are in
general accordance with the idea that a defect in rDNA condensation, brought about
by mHtt, could directly lead to DNA damage in the striatal neurons, thus triggering
apoptosis.
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1.11 Conclusion
We have summarized here the current experimental models of HD, their relative
usefulness, and have discussed molecular mechanism of HD pathogenesis.
Evidence point to the importance of epigenetic mechanisms related to mHtt’s (a)
direct interaction with epigenetic regulators, (b) indirect interaction with regulators
of metabolic states of neurons leading to DNA damage and its persistence, (c) direct
interaction with proteins important for chromosome condensation at the rDNA.
Synergistic genetic interactions between mHtt and p53 or PGC1-α or both appear
to be amplifier mechanisms of HD progression. A better understanding of the
mechanisms of molecular pathogenesis of HD should be possible in the context of
integrated networks of genetic modifiers. We have suggested areas of future
experimental approaches to better understand the molecular pathogenesis of HD,
such that this crippling disease becomes amenable to rational drug development.
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1.12 Tables and Figures

Figure 1.1 Clinical progression of Huntington’s disease as a function of
accumulation of mHtt protein.
The Y-axis on the left represents mHtt accumulation in the brain; y-axis on the
right represents cognitive, motor activity. Axes are in arbitrary units. There is a
substantial heterogeneity among patients as to when salient markers become
visible, the age of onset of clinical presentations, the rate of progression of the
disease and the time of death since diagnosis. While CAG repeat length at HTT is
a strong determinant of the age of onset, there is still much variability among
individual patients, indicating the influence of genetic or epigenetic modifiers as
well as environmental effects
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Figure 1.2 Models of mechanisms of action of mHtt.
Full length mutant Huntingtin protein (mHtt) interferes with the interaction of p53
with its regulator Mdm2, stabilizing p53 and inhibiting the latter’s downstream
proteasomal degradation. N-terminal fragments of mHtt (mHtt*) enter the
nucleus leading to persistent transcription of many genes by p53, triggering the
synthesis of pro-apoptotic proteins, such as Bax and Puma, eventually causing
mitochondrial destruction. mHtt* also inhibits CREB and TAF4 to decrease the
expression of transcriptional co-activator PGC1-alpha, leading to increased levels
of reactive oxygen species (ROS) and cytochrome C release from the
mitochondria, and also defects in the synthesis of electron transport chain
components. These subsequently lead to mitochondrial fragmentation, and cell
death. mHtt (mHtt*) also inhibits protein deacetylase activity of SIRT1 which
leads to abnormal accumulation of hyperacetylated FOXO3a and p53 proteins.
Hyperacetylated FOXO3a and p53 participate in abnormal transcriptional factor
activity, the latter specifically involving DNA damage response genes.
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Figure 1.3 Chromosome condensation defects in Huntington’s disease.
mHtt inhibits the function of ribosomal protein L11p, condensin proteins
Smc2p/Smc4p, UBTF and other chromatin proteins, which are responsible for
nucleolar rDNA condensation. These may lead to fragmentation of nuclear DNA,
initiating DNA damage response, also involving p53, leading to triggering of
apoptosis. Subsequent mitochondrial dysfunction may also contribute to apoptosis
as described in Figure.1.2. Black boxes represent rDNA loci; red dots on
chromosomes represent condensed rDNA regions including rRNA transcripts in
the nucleolus.

Chapter 2
2 Constructing the Huntington’s disease
Integrome
2.1 Introduction
Huntington disease (HD) is a rare neurodegenerative disorder inherited in an
autosomal dominant manner which is thought to be caused by a CAG triplet repeat
expansion in exon1 of the Huntingtin (HTT) gene. HD is one among the group of
PolyQ repeat disorders that include spinocerebellar ataxias, dentatorubralpallidoluysian atrophy (DRPLA) and spinal and bulbar muscular atrophy, X-linked
1 (SMAX1/SBMA).(Fan et al., 2014) Other disorders such as Huntington’s disease
-like 1 (HDL1) and Huntington’s disease -like 2 (HDL2) show close resemblance
with the neuropathological and clinical presentation of HD.(Schneider and Bird,
2016) On an average, the age of onset of disease is inversely proportional to the
number of CAG repeats. While these repeat numbers account for approximately
50-70% of the age of onset of data, various genetic and environmental factors
explain the remaining variability in the age of onset.(Djoussé et al., 2003; Project*
and Wexler, 2004) The number of CAG repeats is also an important determinant of
the rate of clinical progression. Individuals with shorter CAG repeats display a
gradual increase in clinical progression than patients with longer CAG repeats.
Clinical features of HD range from subtle changes in cognition and motor control
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(Walker, 2007) to distinct chorea, and profound motor incoordination(Watts and
Koller, 1997; Weiner and Lang, 1989), cognitive dysfunction (Craufurd and
Snowden, 2002), depression and suicidal behavior.(Walker, 2007) The patient
generally succumbs to the disease. Although extensive studies reveal a complex
pathophysiology of this severely crippling disorder, the sequence of events through
which the mutant Huntingtin (mHtt) protein executes its action still remains elusive.

The mHtt protein is thought to exert its effects mostly through a toxic gain of
function via the short N-terminal fragments of mHtt that are produced as a result of
proteolytic cleavage.(Bizat et al., 2003; Cowan and Raymond, 2006; Gafni and
Ellerby, 2002; Gafni et al., 2004; Goffredo et al., 2002; Graham et al., 2006; Kim
et al., 2001; Lee and Kim, 2006; Wellington et al., 1998) Neuronal studies and
mice models of HD also point to a loss of beneficial function of wild-type Htt
protein.(Cattaneo et al., 2001; Faber et al., 1998; Hackam et al., 2000; Kalchman et
al., 1997) Accumulation of PolyQ aggregates also called as intraneuronal nuclear
inclusions (INNs) in the neuronal cells (Davies et al., 1997) due to protein
misfolding is one of the hallmarks of the HD. The overall burden of INNs correlates
with the severity of the clinical symptoms of HD. The cellular stress that builds up
due to increasing levels of INNs unleashes a sustained unfolded protein response
(UPR) and eventual neuronal apoptosis.(Soto, 2003) The normal HTT gene is
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essential for survival in early embryogenesis, but its function, though ubiquitously
expressed in later stages of development, is not well understood. The complexity
of the pathophysiology of HD can be attributed to the tendency of mHtt to
abnormally interact with various other proteins that either do or do not interact with
the wild-type Htt protein in normal conditions. This is compounded by the presence
of the Htt protein at various subcellular locations where it is proposed to participate
in various signaling pathways and/or associate with numerous other protein
partners during its normal course of action.(Cattaneo et al., 2005; MacDonald,
2003; Marcora et al., 2003) Among the several molecular and cellular functions
affected in HD, some important ones include transcriptional activity(Benn et al.,
2005; Luthi-Carter et al., 2000; Schilling et al., 2004), vesicle transport(DiFiglia et
al.,

1995;

Gauthier

et

al.,

2004;

Velier

et

al.,

1998),

synaptic

transmission.(Gutekunst et al., 1999; Li et al., 2000; Luthi-Carter et al., 2000; Sapp
et al., 1999; Trettel et al., 2000; Velier et al., 1998), and mitochondrial
functions.(Benchoua et al., 2006; Bezprozvanny and Hayden, 2004; Panov et al.,
2002)

Curiously, although differentiated cortical neurons affected by HD do not divide,
recent studies have highlighted the role of chromosome dynamics in the
pathophysiology of HD and how epigenetic mechanisms might contribute to DNA
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damage and cell death. SIRT1, whose protein deacetylase activity is inhibited by
mHtt (Jiang et al., 2012), is one such epigenetic player. Several studies have shown
SIRT1 to be important for DNA damage repair in mitotic cells (Tauchi et al., 2002;
Wang et al., 2008) by helping with loading of histone 1 and condensin 1 complexes
on to the mitotic chromosomes.(Fatoba and Okorokov, 2011) Association of SIRT1
with the MRE11-RAD50-NBS1 (MRN) complex, leads to a deacetylated NBS1
that helps in DNA damage detection.(Tauchi et al., 2002) Inhibition of SIRT1 by
mHtt has therefore been thought to interrupt the process of DNA damage
repair(Yuan et al., 2007), further affecting the processes of G2/M DNA-damage
checkpoint arrest, and intra-S phase checkpoint of cell cycle.(Yuan et al., 2007)
SIRT1 is known to be important for chromatin condensation during normal cell
division.(Wang et al., 2008) It functions as a neuroprotective agent through its
protein deacetylase activity on a number of protein substrates such as FOXO3a
(Jiang et al., 2012; Kops et al., 2002; Mojsilovic-Petrovic et al., 2009; Peng et al.,
2010), p53(Bae et al., 2005; Grison et al., 2011; Toshiyuki and Reed, 1995; Yu et
al., 2001), PGC1-alpha (Nemoto et al., 2005) and BDNF(Cattaneo et al., 2001) to
regulate neuronal function including their metabolic states. Such indirect actions of
mHtt through SIRT1 may lead to continuing accumulation of DNA damage.
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Recent studies from our laboratory demonstrated that several rDNA genes encoding
ribosomal proteins, specifically L12p suppresses mHtt toxicity in yeast (Chatterjee
et al., 2013); Yeast L12p is equivalent to the human L11p, and L11p is known to
be directly implicated in triggering apoptosis through the p53 pathway.(Maehama
et al., 2014) An additional connection between mHtt and chromosome
condensation defects exists which is implicated in DNA damage and apoptotic cell
death in mammalian cells.(Blank et al., 2006) Abnormal association of repeatcontaining RNA with nucleolar protein complexes is known to cause “nucleolar
stress” and activates the p53 pathway to trigger cell death(Kreiner et al., 2013), a
process shown to be important for HD.(Tsoi et al., 2012) Thus, while neurons do
not undergo mitosis, their death might indeed be triggered by rDNA condensation
defects through the same molecular pathways that are used in mitotic DNA repair.

Considering the above, it is now increasingly evident that the phenotype of HD is
an outcome of numerous processes initiated by the mHtt protein (Culver et al.,
2012) along with other proteins that act as either suppressors or enhancers of the
effects of mHtt protein and PolyQ aggregates. Detection and analysis of proteins
that physically interact with wild-type and mHtt proteins have provided valuable
information on various molecular and cellular processes affected in the mutant
cells. Physical interactors of Htt proteins have been discovered using yeast two-
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hybrid (Y2H) and in vitro affinity pull-down experiments.(Faber et al., 1998;
Goehler et al., 2004; Holbert et al., 2001; Li et al., 1995; Passani, 2000; Savas et
al., 2008; Wanker et al., 1997; Yamamoto et al., 2006) Such proteomic studies have
identified high-confidence Htt-associated proteins by using both wild-type and
mutant full length Htt (fl-Htt) proteins.(Culver et al., 2012; Shirasaki et al., 2012)
Proteomic analysis of human HD brain specimens reveal several differentially
expressed proteins in substantia nigra (Chen et al., 2012), cortex (Schönberger et
al., 2013) and striatum.(Sorolla et al., 2008) A recent proteomic study of HD and
HDL2 disease brains uncovered several concomitantly affected pathways such as
Rho-mediated signaling, axonal guidance and DNA/RNA processing.(Ratovitski et
al., 2016) While these recent analytical studies have generated long lists of protein
interactions that are affected in HD, the potential of using them to reveal disease
mechanisms, poses interesting challenges considering the high volume data
involved.

Network-based analysis of disease proteomes have provided important clues to
mechanisms of molecular pathogenesis in HD. Such studies have so far been largely
conducted on data derived from yeast-two hybrid protein interaction
experiments.(Goehler et al., 2004; Riechers et al., 2016; Tourette et al., 2014) These
studies have revealed important roles of Rho GTPase pathway (Tourette et al.,
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2014) and, caspase-6 interactors (Riechers et al., 2016) in HD pathogenesis. A
spatiotemporal proteomic study of HD and wild-type mouse brains performed using
Affinity Purification Mass Spectrometry (AP-MS), identified candidate proteins
found in complex with Htt protein and uncovered a modular network of Httinteracting proteins enriched in functions such as proteostasis, microtubule-based
transport and 14-3-3 signaling.(Shirasaki et al., 2012) Construction of separate
protein-protein interaction (PPI) networks for wild-type and mHtt protein have
helped identify new interacting partners of the mHtt protein acquired in the diseased
state.(Basu et al., 2013) Such protein-protein networks alone are of limited value
without additional consideration, such as the functions of groups of these proteins,
which might be affected by the disease.(Kelley and Ideker, 2005)

Building network models by integrating genetic and physical interactions have been
invaluable in understanding the organization and functions of disease
pathways.(Kelley and Ideker, 2005) For example, integrated analyses of multiple
datasets such as genome-wide linkage studies, genome-wide association studies
and genome-wide expression profiling followed by PPI network modeling has
prioritized candidate genes for Alzheimer’s disease.(Talwar et al., 2014) An
interesting approach has been the integration of gene expression and protein
interaction data from HD patients and progressively filtering the resultant HD
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interaction network to predict brain-specific interactors of Huntingtin protein
(Stroedicke et al., 2015).

While protein interactions are valuable tools to explore still unknown molecular
processes and functions, it has been shown that the ability of PPI data alone to
predict interactions and molecular pathways improves with the inclusion of
additional information. Such information may include tissue and cell type-specific
gene expression data and further evidence about highly interacting proteins (Lopes
et al., 2011). To enable functional linkages between PPI networks and biological
functions, studies on model organisms have been of outstanding promise.

To enable functional linkages between PPI networks and biological function,
studies on model organisms have been of outstanding promise. C.elegans, D.
melanogaster and S.cerevesiae models of HD toxicity have enabled the
identification of genetic modifiers of HD (Chatterjee et al., 2013; Faber et al., 2002;
Giorgini et al., 2005; Imamura et al., 2016; Jimenez-Sanchez et al., 2015; Mason
and Giorgini, 2011; Mason et al., 2013; Parker et al., 2004; Silva et al., 2011;
Willingham, 2003; Yamamoto et al., 2006; Zhang et al., 2010). However, the
complexity of the mechanisms of action of these genetic modifiers on their targets
pose a serious challenge for deciphering the causative mechanisms behind the
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disease. It may be speculated that an integrative systems approach that includes
both physical and genetic interactions could be a powerful avenue to decipher the
complexities of this multi-system disorder and simultaneously obtain a
comprehensive depiction of the perturbed molecular processes in HD.

In this study, we construct an orthologous human HD interactome, using human
orthologs of protein interactors of wild-type and mHtt in a mouse HD model
(Shirasaki et al., 2012) combined with genetic modifiers of mHtt toxicity found in
yeast HD models.(Chatterjee et al., 2013; Giorgini et al., 2005; Mason and Giorgini,
2011; Mason et al., 2013; Willingham, 2003) Computational analysis of the
orthologous interactome revealed a modular structure functionally enriched for
DNA damage response, regulation of chromatid cohesion and chromosome
organization, suggesting the hypothesis that these processes might be abnormal in
cells expressing mHtt. We tested this hypothesis by combining a series of gene
over-expression constructs with genes encoding the normal or mutant versions of
the human Htt N-terminal fragments, and observing that 24 yeast genes related to
chromosome dynamics, when over-expressed from multicopy plasmids, suppress
mHtt-mediated toxicity. The computational predictions with the human HD
interactome were confirmed further by an independent computational technique,

39

which allowed the identification of 27 candidate human genes as possible genetic
modifiers of HD. We have validated 3 of these genes in a Drosophila model of HD
The novelty of our approach is an iterative process: by integrating genetic
interaction and protein interaction data from two different model organisms, we
generate an orthologous human interactome, analyze that orthologous interactome
for the presence of molecular functions enriched within topologically defined
modules by unsupervised machine learning, and validate gene candidates as
modifiers of HD in model organisms.

2.2 Method
2.2.1 Interaction data sets
The huntingtin protein interactome was built using published datasets. Five sets of
primary interactors of mHtt protein were retrieved from experiments performed in
yeast (Chatterjee et al., 2013; Giorgini et al., 2005; Mason and Giorgini, 2011;
Mason et al., 2013; Willingham, 2003) and mouse models (Shirasaki et al., 2012)
of HD. Studies performed in yeast HD model(Chatterjee et al., 2013; Giorgini et
al., 2005; Mason and Giorgini, 2011; Mason et al., 2013; Willingham, 2003)
comprise of genetic suppressors and enhancers of mHtt protein, while Shirasaki et
al is a spatiotemporal set of protein interactors identified using AP-MS that form
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complexes with Htt in both wild-type and BACHD mouse brains (Shirasaki et al.,
2012).

2.2.2 Ortholog detection and construction of orthologous HD interactome
Human orthologs (n = 601) of the protein interactors were found using the
Inparanoid algorithm using a threshold of 1 for detecting orthologs(O’Brien et al.,
2005;

Remm

et

al.,

2001)

(R

packages

–

hom.Hs.inp.db_3.0.0,

hom.Mm.inp.db_3.0.0 and hom.Sc.inp.db_3.0.0). The first degree protein
interactions for these human orthologs were obtained by querying the Human
Integrated Protein-Protein Interaction rEference (HIPPIE) database – a human PPI
database which contains an integration of multiple experimental PPI datasets
normalized using a confidence score ranging from 0 to 1 for each protein
interaction.(Schaefer et al., 2012) Protein interactions with a confidence score
larger than 0.3 were chosen for network construction and analysis (Figure S1 in
Text S1).

2.2.3 Network construction and analysis
HD interactome was built using the web-based Cytoscape tool.(Shannon et al.,
2003)

Topological

network

analysis

was

performed

using

NetworkAnalyzer.(Assenov et al., 2008) ClusterONE(Nepusz et al., 2012) was
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used to identify overlapping protein complexes within the HD interactome.
Hierarchical network structure was obtained using Jerarca.(Aldecoa and Marín,
2010) Additional information about ClusterONE and Jerarca algorithms is given in
the forthcoming sections Dendrogram was visualized using the Phylowidget
tool.(Jordan and Piel, 2008)

2.2.4 Gene Ontology (GO) enrichment
GO enrichment of the protein complexes was performed using the g:GOST tool
from the g:Profiler package.(Reimand et al., 2016)

Significant GO enriched

processes and pathways were estimated using the hypergeometric probablity
distribution given by the following equation:

𝑃 =1−

𝑘−1 𝑀 𝑁−𝑀
( )(
)
∑ 𝑖 𝑁𝑛− 𝑖
(𝑖)
𝑖 =0

where, n is the number of genes of interest, k is the number of genes within that list
that are annotated with a GO term, N is the total number of background genes in
the distribution, M is the number of genes within that distribution that are annotated
directly or indirectly with the GO term of interest.(Boyle et al., 2004) False
Discovery Rate (FDR) was controlled using the Benjamini-Hochberg method for
multiple correction.(Benjamini and Hochberg, 1995)
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2.2.5 Yeast strains, media and plasmids
The yeast strains for studying mHtt toxicity study were generous gifts from S.
Lindquist (MIT). The two different versions of the N-terminal Htt fragment from
exon 1 (25Q(normal) and 103Q(toxic)) are integrated into the chromosome of
W303 yeast strain background for expression of poly(Q). W303 is a haploid yeast
strain expressing FLAG-htt-poly(Q)-CFP under GAL1 promoter control in his3
locus and the two strains used in this study are

can1-100, his3-

11,15::FLAGhtt103Q-CFP, leu2-3,112, trp1-1, ura3-1, ade2-1; and can1-100,
his3-11,15::FLAGhtt25Q-CFP, leu2-3,112, trp1-1, ura3-1, ade2-1. Suppressors
genes of smc2-8 were selected from Patra et al 2017.(Patra et al., 2017). They were
individually selected from the MORF (Movable open reading frame)
library.(Gelperin, 2005; Patra et al., 2017) The MORF library contains 5,871 ORFs
in 2μ plasmids with galactose inducible promoter and a URA3 selectable marker.
The plasmid DNAs were isolated separately for further transformation into the
above two yeast strains. The yeast strains having 25Q and 103Q repeats, were
grown in yeast complete media containing 1% raffinose followed by transformation
of each strain with 1μg of individual gene. The transformants were selected on
synthetic defined medium lacking uracil containing 1% raffinose and streaked for
single colonies. A single colony corresponding to each candidate suppressor gene
in each of the two different yeast strains was suspended in liquid broth for serial
10X dilution and titration spotted on synthetic media containing either 2% glucose
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(repression) or 2% galactose (induction). The wild-type strain containing Htt25Q
can grow normally when GAL1-25Q is overexpressed in presence of galactose,
whereas the mHtt strain having Htt103Q should die or show reduced growth in
presence of galactose.

2.3 Results
2.3.1 Construction of HD protein interactome
We compiled a set of 1188 physical and genetic interactors of the normal Htt and
mHtt proteins from published data(Chatterjee et al., 2013; Giorgini et al., 2005;
Mason and Giorgini, 2011; Mason et al., 2013; Shirasaki et al., 2012; Willingham,
2003) (Table S1) and obtained 601 human orthologs that were designated as
primary interactors of Htt or mHtt protein. Next, we acquired the interacting protein
partners of the above 601 human orthologs from HIPPIE (version 1.7), with a
confidence score assigned to each interaction.(Schaefer et al., 2012) A total of
32365 interactions were obtained, which comprised of both direct and indirect
interacting partners of Htt protein. The interaction list was further narrowed down
to 32243 interactions by selecting only those interactions that had a confidence
score of more than 0.45 in the HIPPIE database. An integrated HD interactome was
constructed from this final list of interactions and will be referred to as the
Huntington’s disease integrome (HDI) (Figure 2.1). The HDI is densely connected
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containing 7418 nodes that represent first and second-degree protein interactors of
wild-type and mHtt protein and 31185 edges (self-loops and duplicate edges
removed) that represent total interactions among the protein pairs. Note these lists
of interactions contains two kinds of information (1) orthologous PPI pairs of
mouse proteins mapped to the human proteome, (2) orthologous genetic interaction
pairs of yeast genes mapped to the human proteome. Thus, these lists encapsulate
heterogeneous properties of proteins and genes.

2.3.2 Network properties of Huntington’s disease integrome
The network properties of the HDI have been summarized in Table 2.1 and
discussed in brief in the Appendix. The HDI follows a power-law degree
distribution (Figure 2.2), with a clustering coefficient of 0.140 and a network
density of 0.001 indicating a large sparse network of interactions characteristic of
most biological networks.(Jeong et al., 2000, 2001; Watts and Strogatz, 1998) Out
of the 601 human orthologs identified as primary interactors of the Htt protein, 578
genes are directly connected to each other. The 5 most highly connected nodes with
a degree > 350 are HSP90AA1, YWHAZ, HSP90AB1, VCP and CUL2 which act
as network ‘hubs’ indicating their probable role in HD processes. Indeed, the
binding activity of HSF1 – a master regulator of heat shock proteins such as
HSP90AA1 and HSP90AB1 is known to be altered in Poly-Q cells (ST HdhQ111)
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expressing full-length Htt.(Riva et al., 2012) Both wild type and mHtt are known
to interact with HSP90; a pharmacological inhibition of this interaction leads to
increased clearance of mHtt and degradation through the ubiquitin-proteasome
systems.(Baldo et al., 2012) HSP90AA1 has also been identified has a potential
gene of interest in HD in another study involving microarray analysis of postmortem human brain samples.(Chandrasekaran and Bonchev, 2016) VCP is known
to localize chiefly in the nucleus of the adult neurons and interacts with both wild
and type mHtt protein. Its interaction with mHtt alters the recruitment of VCP to
DNA damage foci causing inhibition of DNA repair (Fujita et al., 2013) and
modulates neurodegeneration. Loss-of-function mutants of ter94 gene in
Drosophila

encoding

for

VCP

act

as

genetic

modifiers

of

neurodegeneration.(Higashiyama et al., 2002) Overexpression of cul-2, a
Drosophila ortholog for the human gene CUL2, is known to suppress an expanded
(128Q)

Htt-

fragment

induced

neurodegeneration

in

the

Drosophila

eye.(Kaltenbach et al., 2007) Taken together, these findings present evidence that
our orthologous HDI displays a ‘network-hub’ driven structure characteristic of a
scale-free topology associated with robust biological interaction networks, where
the major hubs represent genes/proteins known to be important in HD pathogenesis.
Chapter 3 covers the analysis of the integrome using an unsupervised machine
learning approach and the results of validation.
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2.4 Tables and Figures
Table 2.1 Network properties of Huntington's disease integrome (HDI)
Network Properties
Number of nodes
Number of edges
Connected components
Network density
Network heterogeneity
Network diameter
Clustering Coefficient
Average shortest path length
Average number of neighbors (mean
degree)

7418
31185
12
0.001
3.405
9
0.14
3.545
8.408
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Figure 2.1 Workflow to generate and identify candidate genes from the
Huntington’s disease integrome (HDI).
The workflow for the integrome includes integrating physical and genetic
interactors of wild-type and mHtt protein from various HD model organisms
finding the human orthologs (n = 601) for these interactors, and mining a protein
interaction database for secondary interactions. The integrated network thus
constructed contains first and second-degree interactors of the wild-type and mutant
Htt protein.

Figure 2.2 Degree distribution of the Huntington's disease interactome (HDI).
The HDI follows a power-law distribution fit in the form of y = ax-b (a = 1053.7, b
= 1.313 and R2 = 0.857)

Chapter 3
3 Analysis of Huntington’s disease integrome and
candidate gene validation using unsupervised
machine learning
An important approach to understand the biological significance of a large
interaction network is to apply unsupervised machine learning algorithm to reduce
the dimensionality of the data. When the interaction data are reduced to smaller
numbers of subclasses according unbiased methods of dimensionality reduction,
one can then ask whether such classes have biological significance. One such
method of unsupervised machine learning method for dimensionality reduction is
clustering the network members on the basis of some graph-theoretic properties.
We thought that within a large interactome with potentially many false positives,
nodes (genes/proteins) that are connected topologically to other genes/proteins,
especially those within overlapping clusters where connections to the same
members are repeated many times, could provide clues to important biological
functions in common among those proteins belonging to overlapping clusters.
With the aim of detecting highly connected overlapping clusters of proteins within
the HDI,

49

50

3.1 Pre-requisites to choose a clustering algorithm for the HDI.
Considering the heterogenous nature of the information contained in the HDI
network, we devised a list of pre-requisites that needed to be fulfilled that would
help extract biological meaningful information from the graph. Since proteins have
multiple biological functions, and operate in various cellular compartments over
time, a clustering method that captures these overlapping relationships of functions
with each other and also with other proteins was an essential pre-requisite.
Computationally efficiency of the clustering approach and the ability of the
algorithm to scale up to larger networks was also a necessary requisite in choosing
a method. Ability of the algorithm to be robust and produce consistent results, albeit
with some performance degradation, even when a certain level of noise is
introduced in the graph was also an important criterion. Since there is no gold
standard dataset for HD for the algorithm to compare against, we believe, another
essential criterion to be the ability of the algorithm to assess the quality and
accuracy of the cluster output by using an internal validity measure that is built into
the algorithm itself.

Based on the above pre-requisites we chose ClusterONE – an overlapping complex
detection method as the primary clustering algorithm for HDI. While ClusterONE
detects overlapping relationships between clusters, it also was found to be a
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computationally efficient method that could be scaled up to support clustering of
larger networks. Another method Jerarca – a non-overlapping hierarchical
clustering algorithm was used to validate in-silico the findings obtained from
ClusterONE. Jerarca though computationally more expensive – a typical feature of
hierarchical clustering algorithm, compares reasonably well to other algorithms in
the same category Both these algorithms have internal parameters built into them
that ensure that the quality and accuracy of clusters compare favorably to those
found in the literature. These two clustering methods will be overviewed in the
forthcoming sections

3.2 ClusterONE Algorithm
The ClusterONE algorithm (Nepusz et al., 2012) detects potentially overlapping
protein complexes in protein-interaction networks. Typically, a protein complex
within a network is a group of nodes (proteins) that are densely connected to each
other, as compared to the rest of the network. ClusterONE algorithm explores this
inherent property of protein complexes to identify overlapping network clusters.
The algorithm implements a function called ‘cohesiveness’ of nodes to identify the
quality of the nodes included in the complex. Some basic terminology used by the
algorithm to determine cohesiveness of nodes is explained briefly as follows:
Consider the graph G in Figure 3.1 below with a group of vertices V0 (the shaded
gray region)
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The vertices of V0 are called internal vertices, while the vertices not included in V0
are called external vertices. The edge between two internal vertices is called an
internal edge, while an edge between an internal and external edge is called the
boundary edge. The edge between two external vertices is called the external edge.
An internal boundary vertex is an internal vertex that has at least one boundary
edge incident on it. An external boundary vertex is an external vertex that has at
least one boundary edge incident on it.
The ClusterONE algorithm proceeds through three distinct stages:
Step 1: Beginning from a single seed vertex – a protein with the highest degree, the
algorithm greedily adds or removes vertices to find groups of nodes with high
cohesiveness (See below).
Step 2: The next step, measures the extent of overlap between each pair of node
groups and merges those groups that have an overlap score greater than a specified
threshold (an overlap threshold score of 0.8 was used for our analysis). The overlap
score between two protein sets A and B is given as follows (Bader and Hogue,
2003):
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Basically, ClusterONE calculates the overlap scores of each pair of protein set and
builds an overlap graph in which each vertex represents a cohesive group and the
two protein sets are connected by an edge if they have an overlap score more that
the overlap threshold. Groups of proteins that are connected to each other directly
through an edge or indirectly through a path of edges are merged as protein complex
candidates.
Step 3: In this step, the algorithm discards those nodes from complexes that have
size less than 3 proteins or whose density δ is less than a given threshold (0.3 in this
case for weighted networks). The density of a complex with n proteins is defined
as the total weight of its internal edges, divided by n(n-1)/2.
3.2.1 Cohesiveness of nodes:
The algorithm uses the concept of cohesiveness (Nepusz et al., 2012) to greedily
build groups of proteins in the PPI network. Cohesiveness measures how likely the
group of proteins can form a protein complexes.
Let w in(V) be the total weight of edges within a group of proteins V, and wbound (V)
be the total weight of edges that connect the group with the rest of the network.
Then the cohesiveness of V is given by

54

Where, p|V| is a penalty term that models the uncertainty in the data by presuming
the existence of yet undiscovered interactions in the PPI network. The penalty term
is set to 2 for the current analysis. Cohesiveness is a simple and efficient way to
evaluate how well a group of proteins aligns with respect to its w in and w bound
property. An increase in cohesiveness indicates two kinds of subgraphs: a subgraph
with many reliable edges and hence a high w in or a well-separated subgraph with a
low w bound
The algorithm retains computational efficiency during its implementation by
maintaining two variables (wiin and wiout) for every protein i in the network. If we
consider Vt to denote the cohesive subgroup in step t, then,
wiin denotes the total edge weight that connect protein i with members of Vt, and
wiout denotes the total edge weight that connect protein i with non-members of Vt .
A boundary-set of Vt is also retained by the algorithm to calculate the cohesiveness
measure. The cohesiveness after adding protein i, is calculated the above preserved
current variables wiin and wiout of Vt and is given by:
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3.2.2 Evaluating the quality of detected complexes:
Since the amount of information contained in disease proteomes is still incomplete,
it is difficult to construct a gold standard to compare predicted complexes against.
Therefore, in such cases, the quality of the predicted complexes can be assessed by
determining the cellular localization of its protein candidates.(Jansen et al., 2003)
If the protein members within a complex are localized in the same cellular
compartment, then it is highly likely that they are members of the same complex.
ClusterONE uses a ‘co-localization score’(Friedel et al., 2009) using localization
annotations of yeast proteins and a standard overrepresentation analysis of
biological process, molecular function and cellular component terms from the Gene
Ontology to evaluate the biological significance of predicted complexes. The
significance levels of the p-values of this overrepresentation analysis were adjusted
using the Benjamini-Hochberg method.(Benjamini and Hochberg, 1995)
The quality of clusters is also evaluated by calculating the p-value of a one-sided
Mann-Whitney U test performed on the in-weights and out-weights of the vertices.
A low p-value indicates that the in-weights are significantly larger than the outweights, and hence it is more likely that the cluster is a valid finding and not the
result of random fluctuations. While internal quality indices such as Dunn’s index
or Silhouette index are used to measure quality of clusters, these methods are used
to cluster points in a high-dimensional space where a sensible distance or similarity
matrix can be defined. Since ClusterONE is a graph clustering algorithm, the notion
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of ‘distance’ does not apply in our particular case. Hence, based on communication
with the author of the algorithm, the p-value of the detected complexes was decided
to be a suitable internal validation measure to evaluate the quality of a cluster in the
graph,. (Nepusz, 2016)
3.2.3 Results using ClusterONE
An implementation of the ClusterONE algorithm on the Huntington’s disease
integrome revealed 3065 overlapping protein complexes out of which 48
complexes were found to be statistically significant in terms of their p-value. (pvalue < 0.05). 12 complexes out of 48 were further chosen for functional
enrichment analysis. The members of these complexes are shown in Table 3.1
3.2.3.1 Gene Ontology Functional Enrichment
The g:GOST tool.(Ashburner et al., 2000; Reimand et al., 2016; The Gene
Ontology Consortium, 2015) was chosen for detecting the cellular functions
enriched in the selected 12 complexes.
The primary interactors within the HDI (n = 578) are directly connected to each
other through biological and molecular processes representing various protein
transport and mitochondrial functions
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3.2.3.2 DNA repair and chromosome condensation related functions enriched in
HDI
Among the 12 statistically significant complexes (p-value<0.05), we found four
modules specifically enriched for functions related to DNA repair and chromosome
condensation

We name these modules as VCP complex, PSMC complex,

YWHAG complex and CCT complex for convenience (Figure 3.2) The members
of these four complexes were functionally enriched for molecular processes such
as “DNA damage response, signal transduction by p53 class mediator resulting in
cell cycle arrest” (GO:0006977, p-value = 9.7E-49), “G1 DNA damage
checkpoint” (GO:0044783, p-value= 1.3E-46), “cellular response to DNA damage
stimulus” (GO:0006974, p-value = 3.8E-28) and “DNA repair” (GO:0006281, pvalue= 0.00549) (Table S5). More interestingly, biological functions closely related
to chromatin cohesion and chromosome organization such as “negative regulation
of sister chromatid cohesion” (GO:0045875, p-value = 0.00016), “chromosome
organization” (GO:0051276, p-value =0.00582) were also found to be enriched
within three of the four complexes. (Figure 3.2) (Table 3.2). A detailed list of the
enriched GO terms and Reactome pathways and their corresponding gene lists is
given in Table 3.2 and Table 3.3 respectively.
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mHtt interrupts the processes of DNA damage repair including G2/M and intra-S
phase cell cycle checkpoints (Yuan et al., 2007) and chromatin condensation
(Fatoba and Okorokov, 2011) by inhibiting SIRT1 deacetylase activity. Ku70, a
component of the DNA damage repair complex, is also targeted by mHtt for
impairing its DNA-dependent protein kinase function (Enokido et al., 2010).
Considering these and several additional information, we have recently proposed
that mHtt could affect cell cycle checkpoint regulation related to chromatin
condensation defects, chromosome breaks and abnormal DNA repair processes,
including those involved in ribosomal DNA condensation pathways.(Lokhande et
al., 2016) GO enrichment results described here are generally supportive of this
proposal.
Interestingly, functional GO enrichment of the first significant protein complex (n
= 105) revealed enrichment for various GO terms related to mitochondrial functions
and processes. Some of the significantly enriched terms include - “mitochondrial
translation (GO:0032543, p value = 1.35x10-54), “mitochondrion organization”
(GO: 0007005, p value = 1.7x10 -47), “mitochondrial electron transport, NADH to
ubiquinone” (GO:0006120, p-value = 2.5x10-11 ). These findings recapitulate
observations from various animal model studies that have found the role of
functions such as maintenance of electron transport chain (Hausladen and
Fridovich, 1994; Tabrizi et al., 1999, 2000), mitochondrial organization, biogenesis
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(Chakraborty et al., 2014; Damiano et al., 2010; Johri et al., 2013) and mobility
(Chang et al., 2006; Orr et al., 2008; Trushina et al., 2004) in HD.
3.2.4 Scalability of ClusterONE
To ensure the algorithm we used for clustering HDI was computationally efficient
for other datasets of comparable size or larger, we ventured to determine the
scalability of ClusterONE to larger datasets.
Before we tested if the method was scalable, we attempted to find the Big O
notation of the method. Considering that this algorithm forms initial clusters based
on the cohesiveness measure of each node in the graph, we assumed that the initial
step would require a total of n2 operations. The next step involves measuring the
extent of overlap between each pair of node groups formed in the first step. This
step is dependent on the number of groups created in the previous stage and hence
it becomes difficult to formally compute the complexity of the algorithm and assign
a definite BigO notation to the method. This conclusion was drawn after
communication with the author of the algorithm and indicates that the runtime of
the algorithm depends on the exact structure of the network it is trying to cluster.
While there might be artificially constructed graphs that might make ClusterONE
run slowly, these graphs will most likely not be a representative of ‘real’ world
datasets that the algorithm will be confronted with.
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We therefore proceeded to analyze the run time of the algorithm by implementing
it on the entire Human protein-protein interaction (PPI) network from BIOGRID.
The run time on this network with 19634 unique proteins and 270,970 nonredundant interactions was found to be 2 mins 40 secs.
ClusterONE has a scaled-up version of its algorithm that was obtained from the
author of this technique. This version parallelizes the cluster growth phase of the
algorithm by using multiple CPU cores. We implemented this scaled version on
two large datasets –


The Amazon graph - 863 nodes and 925,872 edges



The YouTube graph – 1,13,4890 nodes and 2,98,7624 edges

The run time of the scaled-up version of ClusterONE on the Amazon graph and the
YouTube graph was 7.23 seconds and 2.3 minutes (141 seconds) respectively
Details of the graph properties and the run times are given in Table 3.4. The above
scalability studies were performed using a Window PC laptop with the following
processor:
Processor – Intel(R) Core(TM) i7 – 6500 CPU @ 2.50GHz 2.59 GHz, 2 Cores, 4
Logical Processors (x64-based processor)
3.2.5 Robustness of ClusterONE
To demonstrate the robustness of the algorithm used for clustering HDI, we
subjected the HDI network to the following perturbations:
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Dropping edges weights below a threshold score of 0.5 (~10% edges), 0.6
(~20% edges) and 0.63 (~50% edges)



Rewiring the edges and edge weights within a range of 20% - 100% while
maintaining a constant degree distribution of the graph.

For each perturbation, we noted the number of statistically significant complexes
detected, and calculated the significance of overlap (p-value) of the member of
these complexes with the statistically significant complexes detected from HDI. A
background genome size of 19000 was used for calculating the overlap
significance. A Jacquard’s index and Odds ratio was also determined for each
perturbation. We find that the performance of the algorithm starts showing signs of
degradation when we drop edges with a score of 0.6 and less (~ 20% of the edges).
The network fragments into smaller connected components as the percentage of
dropped edges increases to 50% which is also indicated by a drop in the clustering
coefficient of the graph. (Figure 3.3) On the other hand, rewiring just 20% of the
network edges and edge weights, lead to sharp drop in the Jacquard’s index and
Odds ratio which also indicates a significant departure from the clusters obtained
from HDI. Such a performance degradation is however expected considering that
the HDI graph is a weighted graph and contains carefully curated and scored
interactions between nodes. A perturbation via rewiring essentially alters the
biological information contained in the graph and inadvertently introduces a high
number of false positives in the process leading to performance degradation.
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Table 3.5 summarizes the results of robustness analysis. We conclude that while
ClusterONE can handle a drop of ~20% of weighted interactions comfortably
without affecting the connectedness of the graph, it performance significantly
degrades after 20% or more of HDI edges and edge weights are rewired.
3.2.6 Reproducibility of results
To ensure the results obtained using ClusterONE are reproducible, the Rscripts and
step by step code used to bring about this analysis has been documented in the form
of Jupyter notebooks and have been uploaded on GitHub. This will enable users to
run these scripts on the data themselves and verify the results.
The above clustering approach using ClusterONE can find multiple applications in
other PolyQ disorders such as spinocerebellar Ataxia, dentatorubral-pallidoluysian
atrophy (DRPLA) and spinal and bulbar muscular atrophy, X-linked 1
(SMAX1/SBMA). Other neurodegenerative disorders such as Parkinson’s disease
and Alzheimer’s disease can also find this algorithm useful for analysis. Since the
algorithm creates clusters based on a cohesiveness measure, any biological data
which depicts relationships between two or more proteins, genes, cellular
components, functions or processes could serve as a potential source of input. We
however believe that assigning weights to the edges and carefully curating the input
data allows for elimination of noise to a reasonable extent which has positive
implications on the algorithm output as evident from our HDI analysis.
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3.2.7 Jerarca algorithm
We implemented a different clustering approach on the HD integrome, and
performed an in-silico validation of the results obtained using ClusterONE before
we proceeded find in-vitro and in-vivo support for any of the findings. We
specifically looked at the hierarchical clustering algorithm Jerarca to understand
the hierarchy of HDI.
3.2.7.1 Description of the Jerarca algorithm:
Jerarca (Aldecoa and Marín, 2010) is a suite of three hierarchical clustering
algorithms that converts a PPI network into dendrograms through iterative
hierarchical clustering. The suite consists of three algorithms namely UVCluster (a
modified version), RCluster and SCluster. For purposes of analysis of the HDI, we
have implemented the modified more efficient version of UVCluster to reveal the
hierarchical structure of the network.
The suite implements the following steps to detect a hierarchy in the PPI network.
1. The program reads an input file to create an adjacency matrix A of the
PPI graph; where Aij = 1 if vertices i and j are connected and Aij = 0 if
they are not.
2. An iterative UVCluster algorithm (please refer below for details) is run
depending upon the number of nodes in the network. The ideal number of
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iterations suggested by authors is approximately 10 times the number of
nodes in the network. We have used 70000 iterations for our analysis.
3. Step 3 - A matrix of secondary distances is calculated. For each pair of
nodes, the algorithm saves, the number of iterations for which the nodes
have been separately clustered. The secondary distances are then
computed by finding the ratio of these values to the number of iterations.
4. Step 4 - A dendrogram is built using one of the two phylogenetic
algorithms – UPGMA and Neighborhood-joining. We have used the
UPGMA to build a dendrogram from the secondary distance matrix.
5. Step 5 – The resulting dendrogram is evaluated at each level by using two
indices – modularity (Q) and the Surprise (H) score. The optimal partition
of the tree is saved for both the indices.
The workflow of the Jerarca suite considering UVCluster is given in Figure 3.4
3.2.7.1.1 UVCluster Algorithm
The modified version of UVCluster algorithm(Arnau et al., 2005) iteratively uses
agglomerative hierarchical clustering using the primary distance matrix of the PPI
graph. Based on the number of iterations (N) specified by the user before the
analysis starts, the algorithm generates N clustering solutions by randomly
sampling elements of the dataset. The elements in the dataset are clustered using
the average linkage method (Everitt et al 2001). Another parameter that is set by
the user besides the number of iterations is the Affinity Coefficient (AC) which is
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the global stopping parameter for the agglomerative process. The AC is given by
the following equation:
AC = 100[(Pm – Cm)/ (Pm – 1)] where,
Cm is the cluster mean which is the average of distances for all the members in the
clusters, and,
Pm is the partition mean which is the average of the distances for the entire set of
selected proteins.
If Cm = 1, then AC = 100, which signifies that the proteins clustered together have
a distance equal to 1.
A modified version of UVCluster fixes the AC value as 100 (maximally strict) for
the Jerarca suite of algorithms. This value is suitable for PPI networks wherein
many proteins are directly connected to each other and have shorter average path
lengths. The Huntington’s Disease Integrome (HDI) has an average path length of
3.54 and hence an AC value of 100 was deemed appropriate to find protein clusters
in the network. A strict AC value essentially helps to find clique-like subgraphs
within the network.
After obtaining N clustering solutions in the previous step, the algorithm proceeds
to calculate a secondary distance matrix as described in the section above. Such a
secondary distance matrix displays the strength of connection between all pairs of
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elements in the dataset. This distance matrix serves as an input to build a
dendrogram.
3.2.8 Results using Jerarca
The time complexity of the Jerarca algorithm (UV cluster implementation) with an
AC of 100 is O(n2) (Aldecoa and Marín, 2010) Hence we ran this algorithm using
a Trial allocation of 1000 SUs on the Comet cluster of the San Diego
Supercomputing Center (SDSC). The run time of the algorithm was 4 hours and 41
minutes.
Jerarca partitioned the HDI network into 592 distinct non-overlapping clusters
(Figure 3.5) with a modularity (Q) score of 0.31. Examination of the dendrogram
output showed results that were coherent with the output of ClusterONE. Genes
such as FANCI, WAPAL, ESPL1, TUBGCP2 and ANAPC7, which are implicated
in chromosome condensation related functions, were seen to assemble in a single
module (Figure 3.5). Similarly, genes such as ERCC3, UCHL5, SHFM1, NPLOC4,
UFD1L and COPS2 that are related to DNA damage response and DNA repair were
found to be clustered in a separate module. Consistent with results from
ClusterONE, we also found several genes related to mitochondrial functions also
clustered together in a separate module. Such functional segregation in modules is
expected. considering that the hierarchical algorithm does not output overlapping
clusters. These results using an entirely distinct approach recapitulate the
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observations from ClusterONE and lend an additional in-silico support to the
biological quality of data obtained.
We now proceeded to closely examine the clusters obtained using ClusterONE.

3.3 HD integrome reveals novel genes that link chromosome
condensation defects with Htt toxicity
The HDI dataset that yielded a possible link between Huntington’s disease protein
and chromosome condensation/DNA damage repair pathways was only indirectly
derived from yeast genetic interaction data. A fraction of these interactions
contained suppressor and enhancer mutations of mHtt toxicity in yeast. In addition,
they contained 41 ribosomal gene dosage suppressors of mHtt toxicity. Previous
studies with these interaction datasets did not reveal a noteworthy enrichment of
chromosome condensation or DNA damage response pathways among suppressors
or enhancers of mHtt toxicity. We have recently generated a large collection of
gene-dosage suppressors of lethal mutations in yeast (Patra et al., 2017), which
presented an opportunity to ask whether there might be any indirect connection
between suppressors of chromosome condensation defects and genes known to
modify mHtt toxicity.

3.4 Validation in a yeast HD model.
We noticed four yeast homologs among two of the 12 statistically significant
complexes within HDI, detected using ClusterONE, which are known to function
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in chromosome dynamics. These four interactors are SPC24, MSH4, NDC80(TID3)
and NMD3. Among these, Spc24p and Ndc80p are part of core kinetochore protein
complex involved in chromosome segregation. This provoked us to hypothesize
that SPC24 and NDC80 might genetically interact with mHtt in yeast. However,
loss of function mutations in these two genes were not previously recovered as
suppressors or enhancers of mHtt toxicity in previous studies. Therefore, we
hypothesized that gain of function (overexpression) could potentially modify the
phenotype of mHtt expression.

We tested this hypothesis by directly overexpressing SPC24 gene under the control
of a galactose-inducible promoter on a multicopy yeast plasmid (see Methods). This
plasmid was introduced into a yeast strain that expresses a chromosomal copy of
mHtt encoding the N-terminal (103Q), also under the control of a galactoseinducible promoter. If grown on glucose, these cells do not produce mHtt.
However, in the presence of galactose, these cells produce both mHtt and Spc24p
proteins. A control strain contains exactly the same constructs except that the Nterminal fragment of normal Htt is produced in the presence of galactose.
Overexpression of SPC24 was found to suppress mHtt toxicity (Figure 3.6).
Incidentally, SPC24 was also found to be among the set of genes that suppresses
smc2-8 chromosome condensation defective mutant.(Patra et al., 2017) These
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findings led us to hypothesize whether overexpression of smc2-8 suppressors could
suppress mHtt toxicity (Figure 3.7). As a test of this hypothesis, we examined if a
set of suppressors of smc2-8 mutation (including SMC2), and a selected set of
cohesin/condensin genes could suppress mHtt toxicity in yeast. We examined 36
suppressors of smc2-8 mutant and seven condensin/cohesion related genes, which
were not previously described as modifiers of smc2-8.

Results showed that

approximately 50 percent of these genes (23 of 43 tested), suppressed mHtt toxicity.
The panel that tested for SPC24, is shown in Figure 3.6. Since these 23 genes are
all known to function in chromosome condensation/cohesion processes, these
results are consistent with the hypothesis that mHtt toxicity is related to these
processes.

3.5 Identification of candidate genes
Emboldened by the results with yeast genes, we ventured to look for genes with
similar functions in HDI because we thought chromatin condensation/dynamics
related genes in humans might indeed play important roles in HD. We specifically
chose a subset of 27 candidate genes (Table 3.6) within the first 12 statistically
significant ClusterONE complexes with the additional criteria that they have
orthologs in Drosophila. Among these genes, FANCI, WAPAL, ESPL1, TRIP12,
ANAPC7, UBC, NDC80, TUBGCP2, PPP6C were functionally enriched for
processes such as chromosome organization, regulation of chromosome
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segregation, mitotic cell cycle and cellular response to DNA damage. These
findings are significant considering their enrichment is represented across all the
three aspects of GO classes (biological process, molecular function and cellular
component) and the Reactome pathways (Table 3.2 and Table 3.3)

3.6 Candidate gene validation in a Drosophila HD model
The validation experiments in this section were carried out in collaboration with a
different laboratory and is not a contribution by the author of this thesis. For
purposes of validation, two fully balanced lines: one that stably expresses the
pathogenic Htt variant (128-Q) in Drosophila eye (under the eye-specific
promoter), and one that stably expresses the non-pathogenic Htt variant (16-Q) that
serves as one of the controls was generated. Each of these lines was crossed with
an RNAi, overexpression and/or deletion line from the list of 27 potential
interacting genes. The phenotype of the double transgenic flies was assessed and
compared to the driver-alone control and to the eye expressing the non-pathogenic
Htt variant. Any suppression or enhancement of the phenotype strongly suggests a
genetic interaction.

Using this approach, it was found that a loss of function of NPLOC4 (Npl4) gene
in drosophila suppresses mHtt effects in the eye. A loss of function of TUBGCP2
(Grip84) gene was also found to suppress mHtt effects in the drosophila eye. On
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the other hand, a loss of function of the NLRC4 (Diap2) gene was found to enhance
the mHtt effects in the drosophila eye.
NPLOC4 is known to form a complex with VCP and UFD1L, which in turn
complexes with FAF1 receptor to promote Endoplasmic-reticulum associated
degradation (ERAD) of polyubiquitinated proteins. (Lee et al., 2013) Additionally,
NPLOC4 is a crucial component of the Cdc48/p97–Ufd1–Npl4 complex which
negatively regulates Aurora B early in the mitosis of human somatic cells. A
depletion of the Ufd1–Npl4 by using siRNA is known to cause defects in
chromosome alignment and in the anaphase. (Dobrynin et al., 2011) These findings
lend support to our assumption that NPLOC4 could be an intermediate partner
influencing the action of mHtt. This makes NPLOC4 an attractive therapeutic
candidate for Huntington’s disease. TUBGCP2 is component of the Gammatubulin complex and is necessary for microtubule nucleation at the centrosome
(Murphy et al., 1998) However, there have been no studies reported so far
documenting its interaction with the Htt protein and its downstream effects. NLRC4
encodes a member of the NLR family and contains the caspase recruitment domain.
It is known to be essential in eliciting an innate immune response to a wide range
of tissues and organisms, thus playing an important role in tissue damage and
cellular stress. (Kitamura et al., 2014; Romberg et al., 2014; Thalappilly et al.,
2006) While the role of caspases in apoptosis and mitochondrial dysfunction in
HD has been studied, its role in causing an auto-inflammatory response leading to
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cellular stress and damage remains to be fully explored. The above findings from
validation experiments throw light on this portion of NLRC4 in causing apoptosis
and neuronal cell death in HD.

3.7 Conclusion
In this study, we have integrated and analyzed a diverse set of human orthologs of
Htt interacting proteins obtained using both physical and genetic studies. The
resulting HDI captured a brief snapshot of the HD pathogenetic process and helped
us identify clusters of genes that were overexpressed for functions related to
chromosome condensation, DNA damage and DNA repair.
In particular, we have identified 27 candidate genes as potential targets that can
alter or modify the progress of HD. Three of these candidate genes NPLOC4,
TUBGCP2 and NLRC4 have been successfully validated in a drosophila model of
HD and could be considered as potential therapeutic targets to alter the course of
HD. Our results demonstrate and support our hypothesis that mHtt affects and alters
the processes related to chromosome condensation and DNA repair eventually
leading to cell death.
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3.8 Tables and Figures
Table 3.1 Members of the first 10 statistically significant complexes detected in HDI by ClusterONE
Complex
No.
1

2

3

Member of complex
MUT,ADCK3,PNPT1,ACADVL,SUPV3L1,C10orf2,FARS2,MTPAP,TFAM,CPT2,MCU,N
DUFS1,PCCB,AFG3L2,TMLHE,NDUFS2,DBT,PYCR2,NME4,NDUFV1,YARS2,GLDC,N
DUFS3,CLPX,AARS2,MTERF4,ACOT9,AASS,ALDH1B1,ALDH1L2,ATAD3B,C6orf203,
CECR5,CHCHD1,CLPTM1,SLC25A10,ECH1,ECI1,FASTKD1,FASTKD2,GADD45GIP1,S
LC25A18,GRSF1,GTPBP10,GRPEL1,MTIF2,ICT1,ISCA1,MALSU1,MMAB,METTL17,R
NMTL1,MTERF3,PMPCB,MRM1,MTG1,NDUFS8,NDUFAF3,NDUFV2,NGRN,NDUFA2,
NDUFA9,NDUFS7,NSUN4,NOA1,POLDIP2,PTCD1,PUSL1,RBFA,MRPL21,MRPL28,M
RPL48,MRPL3,MRPL27,MRPL32,MRPL18,MRPL19,MRPL54,MRPL39,MRPS11,MRPS1
5,MRPS18A,MRPS22,MRPS6,MRPS23,MRPS25,DAP3,MRPS24,MRPS27,RPUSD3,MRP
S7,MRPS17,MRPS18B,MRPS31,HARS2,PARS2,VARS2,SYNJ2BP,TARS2,RARS2,TFB1
M,THNSL1,TEFM,TRUB2,SLC25A1
VCP,RAD23A,RAD23B,PSMD4,UBC,ANXA5,ANAPC7,ARFGAP2,ARIH1,ATXN3,BAI
AP2L1,CDC42EP1,BRAT1,UBQLN1,CAAP1,CDKN2AIP,C3orf17,CCDC132,CCDC134,C
DK2AP1,CENPH,CIDEC,KIAA1524,CNOT10,COG5,COMMD6,COMT,HSP90B2P,ESPL
1,FANCI,G3BP2,TUBGCP2,GOLPH3L,HS1BP3,H2AFJ,HAUS1,HEATR1,HELLS,HOOK
1,HSBP1,INF2,NPLOC4,LRIG1,MAP7D3,NGLY1,NMD3,DDIAS,PPP6C,UFD1L,PTCRA,
UBE4B,POLR3C,SPAST,SPC24,TAF6L,TBC1D10B,TBC1D9B,SCD,CLN6,DCAF11,MSH
4,RHBDL3,UBE2J1,UBXN11,GTF3C3,GTF3C5,TMEM33,TRIP12,ULK3,VIL1,WAPAL
NAPA, SNAP25, STX1A, ANKRD35, STXBP1, STX1B, STX2, CCSER2, KIAA0319L,
LAMA4, MYH7B, CPLX1, SLC6A5, SLC6A9, SCNN1A, STXBP2, SNAP23, UNC13B,
VAMP8, STMN4, STX17, CAPG, CCDC93, FAM161B, FGB, FUBP3, SLC6A2, SCRT1,
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Complex
No.

4

5

6

7

Member of complex
SNPH, STXBP5, TTC3, TXLNA, TXLNB, ZNF189, ZNF226, ZNF254, ZNF526, ZNF799,
VAMP2, TRIM14, TSPAN7, TXLNG, UACA, VAPB
YWHAZ, YWHAH, HDAC4, HDAC7, MARK2, NEDD4L, PARD3, MST1R, MARK1,
MARK3, PARD6G, PRKCI, CDC25B, PARD6A, SFN, BSPRY, EFNB3, KRT19, LDB1,
PDE1A, SNX24, POTEKP, ACTN3, ADRA2C, ARL6IP1, ATL2, ATL3, CTH, CHTOP,
CIC, DCAF7, TSFM, HIST2H2BF, EIF5B, HECTD4, CMPK1, WWC1, MEF2C, MYH3,
NAPSA, NUFIP1, PGLYRP1, PRIM2, ADSSL1, REEP6, RPRD1A, SMC5, SUPT6H,
SRGAP1, SRSF8, TNS1, SNRPD2P1
ADRM1, UCHL5, RAD23A, RAD23B, PSMD4, PSMA1, PSMC4, PSMC2, PSMD3,
SHFM1, PSMD6, CIITA, PSMC5, PSMD2, COPS2, PSMD8, PSMA2, PSMD13, EPHA8,
ERCC3, POLR2M, HERPUD1, PSMD7, NDC80, NLRC4, PCDH10, GTF2F1, USP14,
ZCCHC8, PSMC6, PSMC1, PSMC3, HTR1E, ATG4C, PAAF1, PSMB2, PSMD10, PSMD5,
RIOK3, POLR2M, MYZAP, PSMD14, ESRRG, HNF4G, MYO18B, PTGS2, PLEKHO1,
PSMB9, PSMD1, RORA, PSMA8, PSMB6, PSMB8, PSMD11, PSMD12, HMOX1,
JKAMP, NUB1, ACTR3B, TSPYL2, RARB, RARG, SUGT1, ST18, TEKT4, UBLCP1,
XBP1P1
CTNNB1, CTNNBIP1, CDH1, CTNNA1, JUP, CDH10, CDH17, CDH18, CDH5, CDH6,
AJAP1, BOC, CDH11, CDH7, CDH8, CDH9, CDON, DLG5, JRK, LEF1, PCSK1,
NEURL2, PROP1, TCF7L2, UHRF2, VEZT, CTNND1, FOXO4, SOX6, TAX1BP3,
BCR/ABL
YWHAG, YWHAH, HDAC7, MARK2, NEDD4L, PARD3, MARK1, MARK3, SIMC1,
FARP2, HOXC10, LATS2, MAP3K6, PRPF4B, RMDN3, SFN, CAMSAP2, CCS, CKAP2,
EPN2, FAM65B, FRY, INPP5E, JAKMIP1, KRTAP195, KRT34, KRT35, KRT37, KRT38,
KRT82, LRCH3, LTB4R, MPHOSPH9, NELFE, PRLR, TRIM21, SHCBP1, SHKBP1,
SHPRH, SYNPO, USP37, VANGL2, ATP6V0B, IGKV1-12,170549
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Complex
No.
8

9
10
11
12

Member of complex
PPP2R2B, HDAC3, RFWD2, PPP2R2A, ATG16L1, CCT7, CCT8, CCT4, CCT5, CCT2,
TCP1, TBK1, PPP2R2C, METTL20, METTL21B, RPAP1, PPP2R4, PPP4C, CCT6A,
PPP2CA, BBS7, GCNT1, GPN1, MKKS, PACRG, IGBP1, KDM5A, MLST8, MED31,
PPP2CB, MYBPC2, MOB4, STRN, STRN3, STRN4, PPP2R2D, BBS10, CTTNBP2,
DOCK5, FAM86B2, GPR37, TRAF3IP3, THEG, CCT3, CCT6B, IMPA2, MLX, PARP4
GNB5, GNG2, PDCL, GNB2, GNGT1, GNG10, GNG13, GNG3, GNG4, GNG5, GNG7,
GNGT2, RGS6, RASD2, GNG12, GNB3, GNB4, GNG8
GNB5, GNG2, GNB1, GNB2, KCNJ3, GNG10, GNG11, GNG13, GNG3, GNG4, GNG5,
GNG7, GNGT2, GNG12, GNB3, GNB4
CTBP1, ACTL6B, HIC1, MECOM, LCOR, ZEB1
CTBP1, EHMT1, HIC1, MECOM, LCOR, ZEB1
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Table 3.2 List of GO terms related to DNA repair, DNA damage and chromosome condensation found to be enriched
in PPI network complexes
GO term ID

p-value

No.
of
genes

GO
type

GO term description

List of genes

DNA damage response,
signal transduction by p53
class mediator resulting in
cell cycle arrest
signal transduction
involved in mitotic G1
DNA damage checkpoint
G1 DNA damage
checkpoint

PSMC4, PSMC5, PSMD5,
PSMD8, PSMC6, PSMC1,
PSMD10, PSMD7, PSMA2,
PSMD3, PSMD11, PSMD14,
PSMB2, PSMA1, PSMB6,
PSMA8, PSMD4, PSMC2,
PSMD6, PSMC3, PSMD1,
PSMD2, PSMD13, PSMD12,
PSMB8, PSMB9
PSMC4, PSMC5, PSMD5,
PSMD8, HMOX1, PSMC6,
PSMC1, PSMD10, PSMD7,
PSMA2, PSMD3, PSMD11,
PSMD14, UCHL5, RAD23B,
PSMB2, SHFM1, PSMA1,
PSMB6, PSMA8, PSMD4,
PSMC2, ERCC3, PSMD6,
PSMC3, COPS2, PSMD1,
PSMD2, RAD23A, PSMD13,
PSMD12, PSMB8, PSMB9
MSH4, ATXN3, UFD1L, BRAT1,
RAD23B, FANCI, UBC, TRIP12,

GO:0006977 9.70E-49

26

BP

GO:0072431 1.60E-48

26

BP

GO:0044783 1.30E-46

26

BP

GO:0006974 3.80E-28

33

BP

cellular response to DNA
damage stimulus

GO:0006974 5.90E-05

13

BP

cellular response to DNA
damage stimulus
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GO term ID

p-value

No.
of
genes

GO
type

GO term description

List of genes
PSMD4, VCP, CDKN2AIP,
RAD23A, NPLOC4

GO:0045875 0.00016

2

BP

negative regulation of
sister chromatid cohesion

WAPAL, ESPL1

DNA repair

MSH4, ATXN3, UFD1L,
RAD23B, FANCI, UBC, TRIP12,
VCP, RAD23A, NPLOC4

GO:0006281 0.00017

10

BP

GO:0007084 0.00325

2

BP

GO:0003684 0.00422

3

MF

mitotic nuclear envelope
reassembly
damaged DNA binding

GO:0006281 0.00549

7

BP

DNA repair

GO:0051276 0.00582

12

BP

chromosome organization

GO:0051985 0.00922

3

BP

GO:2001251 0.0101

4

BP

GO:0030472 0.0298

1

BP

negative regulation of
chromosome segregation
negative regulation of
chromosome organization
mitotic spindle
organization in nucleus

PPP2CA, PPP2R2A
RAD23B, ERCC3, RAD23A
PSMD14, UCHL5, RAD23B,
SHFM1, ERCC3, COPS2,
RAD23A
MSH4, WAPAL, ATXN3,
RAD23B, HELLS, ESPL1, UBC,
CENPH, TRIP12, TAF6L,
ANAPC7, H2AFJ
WAPAL, ESPL1, ANAPC7
WAPAL, ESPL1, TRIP12,
ANAPC7
PPP2R4

78

GO term ID

p-value

No.
of
genes

GO
type

GO term description

GO:1903047 1.89E-23

30

BP

mitotic cell cycle process

GO:0000922 0.00551

4

CC

spindle pole

List of genes
PSMC4, NDC80, PSMC5,
NLRC4, PSMD5, PSMD8,
PSMC6, PSMC1, PSMD10,
PSMD7, PSMA2, PSMD3,
PSMD11, PSMD14, PSMB2,
PSMA1, PSMB6, PSMA8,
PSMD4, PSMC2, ERCC3,
PSMD6, SUGT1, PSMC3,
PSMD1, PSMD2, PSMD13,
PSMD12, PSMB8, PSMB9
FRY, CKAP2, RMDN3, LATS2
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Table 3.3 List of pathways found to be enriched in HDI network complexes
Pathway ID

p-value

No
of
gene
s

GO term description List of genes

REAC:69563
REAC:69580

1.9E-45

26

p53-Dependent G1
DNA Damage
Response/ p53Dependent G1 DNA
damage checkpoint

REAC:24678
13

3.9E-35

27

Separation of Sister
Chromatids

REAC:74752

1.3E-25

26

Signaling by Insulin
receptor

REAC:24659
10

1.3E-05

3

REAC:75035

1.67E05

3

MASTL Facilitates
Mitotic Progression
Chk1/Chk2(Cds1)
mediated inactivation

PSMC4, PSMC5, PSMD5, PSMD8, PSMC6,
PSMC1, PSMD10, PSMD7, PSMA2, PSMD3,
PSMD11, PSMD14, PSMB2, PSMA1, PSMB6,
PSMA8, PSMD4, PSMC2, PSMD6, PSMC3,
PSMD1, PSMD2, PSMD13, PSMD12, PSMB8,
PSMB9
PSMC4, NDC80, PSMC5, PSMD5, PSMD8,
PSMC6, PSMC1, PSMD10, PSMD7, PSMA2,
PSMD3, PSMD11, PSMD14, PSMB2, PSMA1,
PSMB6, PSMA8, PSMD4, PSMC2, PSMD6,
PSMC3, PSMD1, PSMD2, PSMD13, PSMD12,
PSMB8, PSMB9
PSMC4, PSMC5, PSMD5, PSMD8, PSMC6,
PSMC1, PSMD10, PSMD7, PSMA2, PSMD3,
PSMD11, PSMD14, PSMB2, PSMA1, PSMB6,
PSMA8, PSMD4, PSMC2, PSMD6, PSMC3,
PSMD1, PSMD2, PSMD13, PSMD12, PSMB8,
PSMB9
PPP2CB, PPP2CA, PPP2R2D
YWHAH, YWHAG, SFN
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Pathway ID

p-value

No
of
gene
s

GO term description List of genes
of Cyclin B: Cdk1
complex

REAC:69278
REAC:73894

0.00040
7
0.00081
8

9

Cell Cycle, Mitotic

7

DNA Repair

REAC:56963
94

0.00163

3

REAC:69473

0.00983

3

DNA Damage
Recognition in GGNER
G2/M DNA damage
checkpoint

WAPAL, TUBGCP2, ESPL1, UBC, HAUS1,
CENPH, PSMD4, SPC24, ANAPC7
UFD1L, RAD23B, FANCI, UBC, VCP, RAD23A,
NPLOC4
RAD23B, COPS2, RAD23A
YWHAH, YWHAG, SFN
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Table 3.4 - Scalability analysis of ClusterONE algorithm
Network

Network size

Human PPI network – Nodes: 19634
BIOGRID
Edges: 270,970
Scaled version of ClusterONE
Human PPI network –
BIOGRID
Amazon graph
YouTube graph

Nodes: 19634
Edges: 270,970
Nodes: 334,863
Edges: 925,872
Nodes: 1134890
Edges: 2987624

Minimum Node
Minimum Overlap
Complex penalty Density
threshold
Size
5
2
0.5
0.8

Run time

5

2

0.5

0.8

16.3 seconds

5

2

Auto

0.8

7.23 seconds

5

2

Auto

0.8

2.3 minutes
(141 secs)

2 mins 40
seconds
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Table 3.5 Robustness analysis of ClusterONE
Network
name

Perturbation

Edges

Nodes

Percent of No. of
Intersection
interactions significant size of
dropped
complexes members of
significant
complexes

ED
network1
ED
network2
ED
network3
EWS
network1

3628

27557

7418

11.6

53

6736

24449

7418

21.6

71

14888

16297

7418

47.7

98

all edges
and weights
shuffled
20% edges
and weights
shuffled
40% edges
and weights
shuffled

31185

7418

0

20

31185

7418

0

9

31185

7418

0

8

EWS
network2
EWS
network3

Overlappi Jaccard
ng p-value index
(overlap
significan
ce) against
a genome
size of
19000
0 e +00
0.68

Odds
Ratio

0 e +00

0.5

148

1.5e -299

0.3

53.5

6.20E-40

0.06

41.2

537∩207 =
38

2.40E-20

0.05

8.24

537∩ 292=
58

1.70E-32

0.075

9.43

537∩ 481 =
412
537∩ 621 =
364
537∩ 722 =
299
537∩72 =
38

891
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Table 3.6 - List of 27 candidate genes with a viable and visible phenotype chosen
for validation in a Drosophila model of HD
Human
Genes
UFD1L
FANCI*
UBC
TRIP12*
NPLOC4
WAPAL*
TUBGCP2*
ESPL1
ANAPC7
PPP6C
UCHL5
SHFM1
ERCC3*
COPS2
NDC80*
NLRC4
SUGT1
YWHAH
YWHAG
SFN
FRY
RMDN3
LATS2*
PPP2CB
PPP2CA*
PPP2R2A
PPP2R4

Drosophila Orthologs
Ufd1-like
FANCI*
Ubi-p63E
Ctrip*
Npl
wpl*
Grip84*
Sse
APC7
PpV
uch-L5
sem1
hay*
alien
Ndc80*
Diap2
Sgt1
14-3-3zeta
14-3-3zeta
14-3-3zeta
fry
CG1575
Wts*
mts
mts
tws
Ptpa
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Figure 3.1 An example graph depicting internal and external vertices and edges
along with the boundary vertex
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VCP complex

YWHAG complex

PSMC complex

CCT complex

Figure 3.2 - Protein complexes within HDI that are enriched for DNA repair and
chromosome condensation related functions.
The primary interactors within these complexes as colored as follows: genes
interacting with wt-Htt (blue), with mHtt (red), with both wt and mHtt (purple).
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0.15
0.14

1900

0.14

Clustering Coefficient

0.13
0.12

1400

0.115

0.11

0.1

0.099

0.09

900

756

0.08

0.08
400

0.07
0.06
0.05

-100
0%

10%

20%

No of Connected components in fragmented
network

Robustness of ClusterONE to edge dropping

40%

Percent of Edges dropped from HDI

Figure 3.3 Robustness of ClusterONE to edge perturbation.
Dropping edges ranging from 10% to approximately 50% leads to a drop in the
clustering coefficient and an increase in the number of connected components in
the fragmented network.
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Jerarca file input form
Format: file iAlg tAlg n

Read list of
interactions

Create adjacency matrix

Iterative
Algorithm

n times

UVCluster

Compute matrix of secondary
distances

Tree Algorithm
(UPGMA)

Compute best partition of tree

Output files printed

Figure 3.4 An adapted workflow layout of the Jerarca
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Figure 3.5 Cladogram of HDI hierarchy
The top left panel shows a hierarchical structure of HDI depicted in a circular
cladogram. The top right panel shows a module containing candidate genes
functionally enriched for chromosome condensation processes. while the bottom
panel shows, the module containing candidate genes functionally enriched for DNA
damage and mitotic cell cycle processes.
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- Gal

+ Gal

25Q- SPC24
103Q- SPC24

Figure 3.6 Suppressors of smc2-8 and condensin-cohesin genes suppress the mHtt
toxicity (103Q) in yeast.
A group of 36 smc2-8 mutant suppressors and seven condensin/cohesion related
genes were tested. 23 genes were found to suppress mHtt (103Q) toxicity in yeast
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suppresses

SPC24p

suppresses

Overexpression
Overexpression of
other suppressors of
smc2-8 mutation

Suppress or
enhance ???

Smc2-8 mutation
smc1

smc3

smc2

mHtt toxicity

smc4

Chromosome condensation defect
Figure 3.7 Hypothesis model of suppressors of smc2-8 mutation suppressing mHtt
toxicity
Overexpression of SPC24, a yeast homolog from one of the significant protein
complexes detected in HDI, suppresses smc2-8 mutation and also suppresses mHtt
toxicity. Hence, we hypothesize that overexpression of a set of genes known to
suppress smc2-8 mutant, can also suppress mHtt toxicity.

Chapter 4
4 Predicting physical interactors of the Huntingtin
protein using Supervised Machine Learning
methods.
Experimental approaches such as Y2H (yeast two-hybrid) mass spectrometry (MS),
Tandem Affinity Purification (TAP) and protein microarrays have been the most
widely adopted method to identify protein-protein interactions (PPIs). While Y2H
is sensitive to detection of potential protein partners, it cannot detect interactions
involving more than two protein partners. Additionally, these interactions are
detected by virtue of their occurrence in the Y2H system and do not affirm their
interaction in a physiological state.
The biological data generated using these experimental approaches though
valuable, is subject to disadvantages; a high number of false positives being an
important one of them. Machine learning approaches utilize the existing knowledge
of protein interactors generated using these experimental approaches and help
predict protein interactors. These methods use various protein features related to
their structure, function or sequence to make PPI predictions to achieve better
accuracy (A. Theofilatos et al., 2011). Other computational methods that integrate
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various protein features into one predictor-classifier model have been able to
accomplish higher accuracy (A. Theofilatos et al., 2011; Chen and Liu, 2005)
In this study, we integrate various protein features such as motifs, domains and their
topological properties in a PPI network, to predict protein interactors of mutant Htt
(mHtt) protein. We propose a Gradient Boosting Modeling (GBM) based classifier
that helps to predict Htt-interacting proteins. This classifier examines the
relationships between the topological characteristics of proteins within a proteinprotein interaction network along with the structural and functional properties of
the proteins to group them as interactors or non-interactors of mHtt protein. We
study the extent of information captured by structural and topological aspects of
proteins and investigate whether this information is sufficient enough to predict wt
and/or mHtt protein interactors.

4.1 Data
4.1.1 Model development dataset:
The machine learning model was built using a set of primary interactors of Htt
protein experimentally detected in wild-type and BACHD mouse brains. This
dataset is spatiotemporal collection of 747 candidate proteins identified using APMS that form complexes with Htt in both wild-type and BACHD mouse brains
(Shirasaki et al., 2012). This dataset was divided into 3 separate, non-overlapping
groups as follows: Group 1 – containing proteins that interact with wt Htt protein
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only, Group 2 – containing proteins that interact with mHtt only and Group 3 –
containing proteins that interact with both wt and mHtt proteins.
4.1.2 Input features
4.1.2.1 Motif and domain properties
Motif and domain information related to each of the three groups in the dataset were
obtained from the Uniprot database (Magrane and Consortium, 2011) and used as
features for the input data.
4.1.2.2 PIN graph-theoretic properties
Additionally, graph properties were computed for each protein in the dataset and
used as feature inputs to the machine learning classifier. To compute these network
properties, we used the protein-protein interactions in mouse, curated by the
BIOGRID database. The mouse PPI network obtained from BIOGRID consists of
8629 proteins and 19828 interactions. The following graph properties were
calculated for candidate proteins in the input set:
(a) Average Shortest Path Length: also, known as the characteristic path length. It
measures the expected distance between two connected nodes in a network.
(Assenov et al., 2008)
(b) Betweenness Centrality: If p,q is the number of shortest paths between
proteins p and q, and p,q(r) is the number of shortest paths between p and q
that pass through protein r in a protein interaction network, then betweenness
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centrality of the protein r is defined as p,q(r) /p,q , where the sum is taken
over all distinct pairs p and q. The betweenness value for each node r is
normalized by dividing by the number of node pairs excluding r: (Freeman,
1977)
(c) Closeness Centrality: it measures the extent to which a protein r is close to all
the proteins in the network. If d(r, s) is the shortest distance between proteins
r and s in a protein network, then the closeness centrality of protein r is
defined as (n - 1)/Σq d(r, s), where n is the total number of proteins in the
network (Beauchamp, 1965).
(d) Clustering Coefficient: it is the fraction of the total possible interactions
among direct neighbors of a protein in a protein interaction network. It is
always a number between 0 and 1 (Watts and Strogatz, 1998).
(e) Degree: is the number of edges connected to a node.
(f) Eccentricity: it the maximum (non-infinite) length of a shortest path between r
and another node in the network. If r is an isolated node, the value of this
attribute is zero.
(g) Neighborhood Connectivity: The neighborhood connectivity of a node r is
defined as the average connectivity of all neighbors of r. The neighborhood
connectivity distribution gives the average of the neighborhood connectivities
of all nodes r with k neighbors for k = 0, 1…. Therefore, if the neighborhood
connectivity distribution is a decreasing function of k, then the network
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displays edges between low connected and highly connected nodes (Maslov
and Sneppen, 2002)
(h) Radiality: it is an index computed as follows:
(Diameter of the connected component of node r) – (Average shortest path
length of a node r) + 1.
It is a number between 0 and 1.
(i) Stress Centrality: is the number of shortest paths passing through a node.
(j) Topological Coefficient: this is a measure attributed to those protein in the
network that are not necessarily directly connected to each other. The measure
is given by TCp = average(J(p,j)/kp), where J(p, j) denotes the number of
nodes to which both p and j are linked, plus 1 if there is a direct link between
p and j and kp is the number of links of node p (Stelzl et al., 2005).
The graph properties of the proteins were calculated using the Network Analyzer
application in Cytoscape (Assenov et al., 2008; Shannon et al., 2003)
4.1.3 Dataset formatting
Variable names for motif and domain information were coded, instead of their long
raw names, with numerical identifiers for classifier models. Additionally, presence
of motif or domain for a certain protein was denoted as ‘1’ while absence of a motif
was denoted as ‘0’. The resultant master dataset had 554 proteins as
rows/observations and motifs, domains and graphical properties (n=779) as
columns/dimensions. Detailed characteristics of the master dataset are given in the
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Table 4.1. Evidently, the master dataset is sparsely populated and has a higher
number of variables than the number of observations. This requires variable
reduction and dimension reduction methods, which is explained in Section 4.2.1
4.1.4 Classification target
For classification, a multivariate prediction approach was initially used to
accommodate the three response variables. However, we later moved on to a
binomial prediction approach for better prediction power and simply focused on
two response variables/groups of proteins viz. (a) proteins that interact with wHtt
only (n = 116) (group1) and (b) proteins that interact with mHtt (n = 438) (group 2
(n = 108) + group 3 (n= 330)). This binary approach to analysis showed an
improvement in the model’s predictive power. The three classifiers used for model
development are addressed in the next section.
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4.2 Methods
4.2.1 Variable and dimension reduction methods
The set of variables that best capture the relationship between the response variable
and the predictor variables was determined by calculating the Information Value
(IV) of the predictor variables (Shannon, 1948). Information value helps in variable
selection during model building. Information value of x for measuring y is a number
that attempts to quantify the predictive power of x in capturing its relationship with
y. Assuming that the target variable y is binary in nature, IV is defined as,
𝟏𝟎

𝑰𝑽 = ∑(𝒃𝒂𝒅𝒊 − 𝒈𝒐𝒐𝒅𝒊 ) 𝐥𝐧
𝒊=𝟏

𝒃𝒂𝒅𝒊
𝒈𝒐𝒐𝒅𝒊

where,
i ranges from 1 to 10, in which the data is divided, 𝑏𝑎𝑑𝑖 is the proportion of bad
accounts captured in the ith division out of all bad accounts in the population and
𝑔𝑜𝑜𝑑𝑖 is the proportion of good accounts in the ith division.
Additionally, Principal Component Analysis (PCA) of motif and domain variables
was used for dimension reduction (Hotelling, 1933; Pearson, 1901). PCA converts
a set of observations into a smaller set of linearly uncorrelated variables called as
principal components through orthogonal transformation thus leading to variable
reduction. Each principal component depicts variability in the data, in a descending
order of magnitude, with the first component capturing the maximum variability.
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4.2.2 Logistic regression with regularization
A logistic regression model depicts the relationship between the categorical
dependent variable (response variable) and the independent feature variables
(predictor variables) by estimating probabilities through a cumulative logistic
distribution function (Wedderburn, 1974). Considering that the response variable
for our dataset is binary in nature, the logistic regression model takes the form of a
Generalized Logistic Model (GLM) through the following equation:
log (

𝜋(𝑥)
) = 𝛼 + 𝛽𝑥
1 − 𝜋(𝑥)

The output of a logistic regression model is the probability that a given protein is
an interactor of either wt Htt, mHtt or both wt and mtHtt protein.
Logistic regression with regularization was used to obtain stable fit to the sparse
data in this study. Regularization methods work by penalizing the coefficients of
the features and minimize the error between the predicted and actual observations
either through L2 regularization (Ridge regression) or through L1 regularization
(Lasso regression) (Tibshirani, 1996). The cost function that needs to be minimized
is also called as RSS (Residual Sum of Squares) and is given by the equation:

Cost (W) = RSS(W) =

𝑀
∑𝑁
̂𝑖 }2 = ∑𝑁
𝑖=1{𝑦𝑖 − 𝑦
𝑖=1{𝑦𝑖 − ∑𝑗=0 𝑤𝑗 𝑥𝑖𝑗 }

2
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where X is the matrix of input features, y is the actual outcome variable, ŷ is the
predicted value of y, w is the weights or the coefficients, N is the total number of
data points available, and M is the total number of features.
Penalizing the coefficients with a regularization parameter helps to avoid a large
emphasis on any one particular feature and also helps to reduce the model
complexity. Lasso regression performs L1 regularization by adding a penalty equal
to the absolute value of the magnitude of the coefficients and is given by the
following equation:
Cost (W) = RSS(W) +  * (sum of absolute value of weights)
𝑁

𝑀

2

𝑀

= ∑ {𝑦𝑖 − ∑ 𝑤𝑗 𝑥𝑖𝑗 } +  ∑|𝑤𝑗 |
𝑖=1

𝑗=0

𝑗=0

Ridge regression performs L2 regularization by adding a penalty equal to the square
of the magnitude of the coefficients and is given by the following equation:
Cost (W) = RSS(W) +  * [sum of square of weights]
𝑁

𝑀

2

𝑀

= ∑ {𝑦𝑖 − ∑ 𝑤𝑗 𝑥𝑖𝑗 } +  ∑|𝑤𝑗 2 |
𝑖=1

𝑗=0

𝑗=0
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4.2.3 Random forest
Random Forest is an ensemble decision tree-based machine learning method that
combines groups of weak tree models to result in a stronger model. This model
grows multiple decision trees, wherein, each tree ‘votes’ for a class based on the
attributes (predictor variables) the tree was built on. The model predicts new data
by choosing the classification that receives the most votes over all the trees
(Breiman, 2001). Random forest model thus reduces the variance of prediction
while retaining a low bias. A lower bias and variance translates to a reduction in
the prediction error and also avoids the issue of over-fitting the model to the training
data.
4.2.3.1 Implementation and Parameters used:
We used the random forest package in R for analysis (Breiman, 2001; Liaw and
Wiener, 2002). All the three types of predictor variables – motifs, domains and
graphical properties were used as input for the Random Forest model. The data was
scaled and centered prior to employing the model. The parameters used to run the
model were as follows:


ntree – number of trees to grow. Higher number of trees gives a better
performance.,



mtry – number of variables randomly sampled as candidates at each split.
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Nodesize – minimum size of terminal node/leaf of the decision tree. A
smaller node size causes the model to capture more noise in the train data.

4.2.4 Gradient Boosting Machine (GBM)
Gradient Boosting is also a process that generates an ensemble of trees. However,
the main premise of this model is the concept of ‘boosting’ that serially adds new
prediction models to the ensemble. A new weak, base-learner model is trained at
every iteration based on the negative gradient of the loss function of the entire
ensemble obtained till that point (Friedman, 2001; Natekin and Knoll, 2013). Since
our response variable is binary in nature, we used a ‘binomial’ distribution of the
variable to calculate the loss of function gradient. The model complexity is
controlled by using a shrinkage factor that reduces the impact of each base-learner
model added to the ensemble. Shrinkage penalizes the magnitude of each iteration
and reduces the size of additional steps. Such a method helps to improve the model
accuracy through a series of smaller steps rather than a few large steps (Natekin
and Knoll, 2013) The parameters used to run the model were as follows:


n.trees – the total number of trees to fit which is equal to the number of
iterations



cv.folds – number of cross-validations to perform



interaction depth – the maximum depth of variable interactions
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n.minobsinnode – minimum number of observations in the terminal nodes
of the trees.



shrinkage – also known as learning rate or step-size reduction parameter
for the model that is applied to each tree during expansion.

4.3 Results
The master dataset was prepared before model training and testing, first, by
imputing the missing values in the dataset. The missing values in the motif and
domain predictor variables were replaced with “-1” while the missing values in the
topology/graphical predictor variables were imputed with the mean of their
respective column data. The 769 predictor variables in the master data, which
consist of motif, domain, and graph-theoretic properties, were then reduced
dimensionally using two approaches – (a) Information Value (IV) and (b) Principal
Component Analysis (PCA)
4.3.1 Variable and dimension reduction
Figure 4.1 shows the information values of the predictors in descending order. The
IV of the motif, domain, graph-theoretic variables ranged from 0.2256 to 0.0108.
IV cutoffs of 0.1, 0.056 and 0.055 were initially selected for variable reduction.
Among these, an IV cutoff ≥ 0.056 was chosen for variable reduction because of
the large plateau, corresponding to 0.055, as seen in Figure 4.1. The accuracy of a
lasso regression model using this cutoff value was found to be the best as well.
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To reduce the dimension of the input variables, we also tried PCA analysis,
applying only on motif and domain variables since they account for a vast majority
of the input variables.
PCA on the motif and domain variables (n = 769) revealed 554 principal
components (PCs). The three leading PCs captured most of the variance in the input
data viz. 33.5 %, 7.9 % and 5.3 % respectively (Figure 4.2). These top three PCs
were then combined with 10 graph-theoretic variables to form a development
dataset for further testing.
4.3.2 Logistic regression with regularization
We have performed a series of experiments using the logistic regression with Lasso
regularization to determine the best variable/dimension reduction approach. The
following set of experiments were considered with various configurations of input
data:
1. Experiment 1 – Raw input of master dataset with imputed missing values:
779 predictor variables
2. Experiment 2 – [Variable selection of motif and domain variables using an
IV cutoff of ≥ 0.056]. + [Topology/Graphical predictors]:157 predictor
variables
3. Experiment 3 – [Variable reduction of motif and domain variables using
PCA] + [Topology/Graphical predictors]: 13 predictor variables
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Because of the small sample size, each experiment is evaluated using 10-fold crossvalidation. 10-fold validation splits the original dataset randomly into 10 samples
of equal size. Out of these 10 samples, one is retained as a validation dataset, while
the remaining 9 samples are used as a training set. This cross-validation process is
repeated k times (k = 10 in this experiment), with each of the 10 samples used
exactly once as a validation dataset. This method therefore makes sure that all the
observations are used for both training and validation while each observation gets
to be used exactly once as a validation sample.
The AUC values of regularized logistic regression using the lasso, elastic-net and
ridge regularization are given in the Table 4.2. AUC values for experiment 1 with
10-fold cross-validation ranged from 0.611 (Lasso and Elastic-net) to 0.584
(Ridge). For experiment 2, they ranged from 0.621 (Lasso and Elastic-net) to 0.619
(Ridge). For experiment 3, AUC values were 0.615 (Lasso), 0.613 (Elastic-net) and
0.599 (Ridge). Among the 3 different regularization methods, Lasso performed the
best in all 3 experiments although the Elastic net results were very close to those of
Lasso.
Among the three experiments, experiment 2 with variable selection by IV gave the
best prediction accuracy (AUC = 0.621) in 10-fold cross-validation. Note that the
performance of all three experiments with Lasso is very close, with AUC values
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ranging between 0.611 and 0.621. Such minimal differences can be explained by
the built-in variable selection methods within Lasso itself.
4.3.3 Lasso with data segmentation
We further adopted a segmentation approach to achieve better prediction accuracy
with the Lasso model by dividing the Experiment 2 dataset into four segments as
follows:
1. Lasso Segment 1- Motif-Topology segment - containing proteins with
only motif and topological properties as the predictor variables (48
proteins, 157 predictor variables)
2. Lasso Segment 2- Domain-Topology segment – containing proteins with
only domains and graphical properties as the predictor variables, (231
proteins, 157 predictor variables) and
3. Lasso Segment 3- Motifs and Domain-Topology segment- containing
proteins with motifs, domains and graphical properties as the predictor
variables (35 proteins, 157 predictor variables)
4. Lasso Segment 4 – Only Topology segment – containing proteins with
only graphical properties as the predictor variables (240 proteins, 157
predictor variables).
Considering the low sample size of Segments 1 and 3, in-sample predictions were
obtained for these segments using LOOCV (Leave one out cross-validation). The
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AUC values for all the four data segments range from 0.6 to 0.85 (Table 4.3 and
Figure .4.3) Though these values suggest a better prediction accuracy, it should be
noted that in-sample predictions usually depict an optimistic picture of the model
fit and the model accuracy more than often drops after using repeated crossvalidation.
Nonetheless, these AUC values, encouraged us to believe that a segmentation
approach using other models could help us reach better prediction accuracies.
4.3.4 Random forest
Random forest is a decision-tree based ensemble model known to reduce the
variance and also retain a low bias in its model predictions, thus balancing accuracy
and complexity of the model. A series experiments were conducted by varying two
main hyper-parameters used in Random forest, the number of trees (ntree) and the
number variables available for splitting at each node (mtry). The 10-fold crossvalidated AUC values from these experiments are given in Table 4.4.
The AUC values ranges from 0.54 to 0.594, which are lower than the logistic
regression with Lasso regularization. Experiment 2 with variable selection by IV
again revealed the best prediction accuracy (AUC = 0.594, ntree = 500, mtry = 12)
in 10-fold cross-validation among all the parameter tuning experiments. The
variable importance for proteins interacting with mutant Htt in experiment 2 is
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shown in Figure 4.4. It was found that Random forest relies heavily on the graphical
properties of the proteins while fitting the model.
One of the explanations for a lower predictive power of the Random forest model
could be the small sample size in our data. Random forest works well by
intentionally overfitting the data with deep bushy trees and averaging out these
overfit and diverse trees. The small samples size in our data makes it difficult to
create diverse overfit trees, thus hindering Random forest’s performance.
4.3.5 Gradient Boosting Machine (GBM)
GBM is another tree-based ensemble model by reducing bias step-by-step using
shallow trees. A GBM model was used to fit the input data for all the three
experiments, which examine the effect of variable and dimension reduction. For
these initial experiments, the following parameters were used:


5000 trees with 10-fold cross-validation to determine the optimal number
of trees



interaction depth of 1



number of minimum observation in each node equals to 1



shrinkage of 0.001

Initial implementation of the GBM algorithm on all the three experiments showed
that the AUC ranged from 0.584 to 0.6, with experiment 2 obtaining the highest
AUC (0.6) among the three experiments (Table 4.5). Experiment 2 selects variable
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by using Information value >= 0.056 and this turns out to be consistently the best
method across all machine learning algorithms we tested.
Since GBM has more hyper-parameters to tune than the other machine learning
methods we tested so far, we decided to conduct additional experiments to check
the sensitivity to different hyper parameters. The hyper-parameter tuning
experiments were conducted after the variable selection by IV (Experiment 2). The
experimental design and the AUC values from 10-fold cross-validations are shown
in Table 4.6. In these experiments, the interaction depth were set to 1 to avoid
overfitting and 5000 trees with 10-fold cross validation was used within the fitting
process to determine the optimal number of trees. Two key parameters, shrinkage
and the minimum number of observation in each node, were varied.
It was found that a shrinkage factor of 0.001 and a minobsnode of 10 gave the
highest AUC of 0.61 for experiment 2. This result is better than that of Random
forest (AUC = 0.594) but is not as good as the logistic regression with Lasso
(0.621).
4.3.6 GBM with data segmentation
Encouraged by the prospect of better prediction accuracy using data segments, we
adopted a segmentation approach with the GBM model and divided the master
dataset into three segments as follows:
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5. Segment 1- Motif-Topology segment - containing proteins with only
motif and topological properties as the predictor variables (48 proteins, 60
predictor variables)
6. Segment 2- Domain-Topology segment – containing proteins with only
domains and graphical properties as the predictor variables, (231 proteins,
596 predictor variables) and
7. Segment 3- Motifs and Domain-Topology segment- containing proteins
with motifs, domains and graphical properties as the predictor variables
(35 proteins, 143 predictor variables)
Note that the number of input predictor variables vary for each segment since the
set of proteins in each segment contains a different number of motifs and/or
domains.
PCA analysis was used for motif and domain variable reduction for the above
segments. The following set of GBM experiments were considered with various
configurations of input data:
1. GBM Segment Experiment 1 – [Variable selection of motif variables
using PCA]. + [Topology/Graphical predictors]: 22 predictor variables
2. GBM Segment Experiment 2 – [Variable selection of domain variables
using PCA]. + [Topology/Graphical predictors]: 95 predictor variables
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3. GBM Segment Experiment 3 – [Variable reduction of motif and domain
variables using PCA] + [Topology/Graphical predictors]: 23 predictor
variables
For these experiments, the following parameters were used:


5000 trees with 10-fold cross-validation to determine the optimal number
of trees



interaction depth of 1



number of minimum observation in each node equals to 1



shrinkage of 0.001

The 10-fold cross-validated AUC values from these experiments are given in Table
4.7. AUC values for all the three experiments range from 0.55 to 0.88. GBM
Segment Experiment 1 with motifs and topology as predictor variables revealed the
best prediction accuracy (AUC = 0.88, ntree = 5000, shrinkage factor = 0.001,
n.minobsnode = 1, interaction depth = 1).
4.3.7 Important Predictor variables
The above results demonstrate that logistic regression with Lasso gives better
prediction accuracy for experiment 2 among the three experiments that use IV for
variable reduction. However, data segmentation allows us to achieve much better
prediction accuracy using the GBM model, with GBM Segment Experiment 1
revealing the best AUC among the three data segment models (Figure 4.5).
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We therefore proceeded to examine the variables of importance found from the
GBM Segment Experiment 1. Table 4.8 shows the top 5 important variables for
GBM Segment Experiment 1 in predicting proteins that interact with mutant Htt
protein. Among the graphical properties of proteins, degree, average shortest path
length, betweenness centrality and neighborhood connectivity were found to be the
most important predictor variables. This is indeed true to imagine intuitively as a
protein with numerous interacting proteins is more likely to interact with
Huntingtin protein. Next, we examined the motif variables that contributed to the
PC4, PC6 and PC10. Important motifs in the list were found to encode for an amino
acid sequence relating to nuclear localization signals in proteins (Table 4.9). These
specific proteins are encoded by genes such as RAB3D, RAB3A and RAB3B which
are known to function in GTPase mediated signal transduction pathways and
vesicle mediated transport. We also find the gene NPM1 that encodes for a protein
that is essential for ribosome biogenesis, centrosome duplication, histone assembly
and suppression of p53/TP53. Another set of proteins SLC25A4p and SLC25A5p
are involved in chromosome segregation and in catalyzing exchange of ADP with
mitochondrial ATP across the inner mitochondrial membrane. The above findings
recapitulate the observations made in various animal and cell models of HD and
therefore lend support to the results obtained by the GBM model.
We also examined motifs and domains of relative importance as found by the Lasso
regression model (Table 4.10). Important motifs in the list were found to encode
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for an amino acid sequence relating to nuclear localization signals in proteins
(Table 4.11). Other motifs were found to encode a SUMO paralog- specific binding
sequence in proteins. Proteins containing these motifs are encoded by genes such
as HNRNPQ, HNRNPA2B1 and LMNB1. HNRNPQ, HNRNPA2B1 are nuclear
ribonucleoproteins involved in pre-mRNA processing in the nucleus, mRNA
processing, RNA binding and splicing. HNRNPA2B1 has been shown to bind to
telomeric DNA sequences thus protecting telomeric DNA from digestion. It is also
involved in chromatin regulation and telomere extension. LMNB1 is a component
of the inner nuclear membrane and is thought to interact with chromatin. DDX4p,
a protein encoded by the gene DDX4 has ATP-dependent helicase activity and is
involved in translational control and gene silencing processes by RNA in the
mitotic cell cycle phase.
Similarly, proteins containing domains of importance are encoded by genes such as
HIST1H1C, HIST1H1E and HIST1H1B that are members of the histone family
(Table 4.11). Histones are required for condensation of nuclear chromatin and are
known to regulate gene transcription to chromatin remodeling and DNA
methylation. Histones are also involved in cellular response to stress. Another set
of proteins containing domains of importance are encoded by the genes such as
RAD23A and RAD23B that are known to play an important role in DNA nucleotide
excision repair and in generating a cellular response to DNA damage. RAD23B is
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specifically involved in global genome nucleotide-excision repair (GG-NER) and
in modulating proteasomal degradation of ubiquinated proteins.

4.4 Conclusion
Our results demonstrate the informative value of motifs, domains of proteins in
predicting interactors of mHtt. We show that graph theoretic properties of these
protein interactors also help to determine a possible existence of interaction with
Htt. Considering the sparse nature of predictor variables, we show that while using
Information Value (IV) for variable reduction to provide us with better prediction
accuracy, a segmentation approach using the GBM model coupled with PCA for
dimension reduction, enables us to reach a higher prediction accuracy. The GBM
model specifically reveals the importance of motifs and topology variables in
predicting protein interactors of mutant Htt. The protein motifs of relative
importance detected using this approach are known to annotated with functions
such as vesicular transport, mitochondrial permeability and GTPase activity; all of
which are established cellular processes known to be affected in HD. Additionally,
we show that motifs and domains of importance required to predict proteins
interacting with mHtt, as found by the Lasso model are annotated with functions
such as condensation of nuclear chromatin, DNA nucleotide-excision repair, DNA
and chromatin binding and cellular response to stress. These findings, support our
assumption that mHtt interferes with chromosome condensation and DNA repair
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processes and leads to accumulation of DNA damage in neuronal cells eventually
leading to apoptosis.
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4.5 Tables and Figures
Table 4.1 - Characteristics of data fed to the classifiers
Proteins

M1 …
Mxx

P1 –
Px

Only motif
information

Px –
Py
Py - Pz
Pz –
P554

MyyMzz

D1 ...
Dxx

Dyy …
Dzz

Topology

Response
variables

Topology
Both motif and
domain
information

Topology
Only
domain
Topology
information
Only
Topology
information

* Number of rows (proteins) = 554
* Number of predictors (motifs, domains and topology) = 779
* Response variables (Group 1, Group 2 and Group 3) are binary in nature.

Group 1,
Group 2,
Group 3
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Table 4.2 – Area under curve for regularized logistic regression using Lasso,
Ridge and Elastic-net models from 10-fold cross-validation experiments.
The predictor variables include motifs, domains and graphical properties of the
proteins.
Regularized Regression - AUC values
(Predictor variables include motifs, domains and graphical properties)
Experiment 1 – Raw input of master dataset with imputed missing
values
Lasso ( = 1)
Ridge ( = 0)
Elastic net ( = 0.5)
0.584
0.61
10-fold CV
0.611
Experiment 2 – [Variable selection with an IV cutoff >= 0.056]
Lasso ( = 1)
Ridge ( = 0)
Elastic net ( = 0.5)
0.619
0.62
10-fold CV
0.621
Experiment 3 - [Top 3-PCs on all motif/domain information without IV
filtering] + [Topology/Graphical predictors]
Lasso ( = 1)
Ridge ( = 0)
Elastic net ( = 0.5)
0.599
0.613
10-fold CV
0.615
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Table 4.3 Area under curve for data segments of Experiment 2 obtained using the
Lasso regression model.
The predictor variables include motifs and/or domains and graphical properties of
the proteins.
Experiment 2 - Data Segmentation
Lasso regression - AUC values
(Predictor variables include motifs, domains and graphical properties)
Segment 1 – Motif - Topology Segment (48 proteins and 157 predictor
variables)
Lasso ( = 1)
In-sample predictions (LOOCV)
0.787
Segment 2 – Domain - Topology Segment (231 proteins and 157
predictor variables)
Lasso ( = 1)
In-sample predictions (LOOCV)
0.597
Segment 3 – Motif and Domain - Topology Segment (35 proteins and
157 predictor variables)
Lasso ( = 1)
In-sample predictions (LOOCV)
0.848
Segment 4 – Only Topology Segment (240 proteins and 157 predictor
variables)
Lasso ( = 1)
In-sample predictions (LOOCV)
0.669

118

Table 4.4 - Area under curve for random forest model from 10-fold crossvalidation experiments.
Predictor variables include motifs, domains and graphical properties of the
proteins
Random Forest - AUC values
(Predictor variables include motifs, domains and graphical properties)
Experiment 1 – Raw input of master dataset with imputed missing values
mtry = 5 mtry = 10 mtry = 12 mtry = 13 mtry = 15
10-fold cv
0.566
0.573
0.563
0.57
0.57
(ntree = 500)
10-fold cv
0.559
0.576
0.577
0.58
0.575
(ntree = 1000)
Experiment 2 – [Variable selection with an IV cutoff >= 0.056]
mtry = 5 mtry = 10 mtry = 12 mtry = 13 mtry = 15
10-fold cv
0.585
0.577
0.594
0.58
0.581
(ntree = 500)
10-fold cv
0.584
0.581
0.59
0.581
0.579
(ntree = 1000)
Experiment 3 - [Top 3-PCs on all motif/domain information without IV
filtering] + [Topology/Graphical predictors]
mtry = 5 mtry = 10 mtry = 12 mtry = 13 mtry = 15
10-fold cv
0.564
0.57
0.554
0.569
0.569
(ntree = 500)
10-fold cv
0.567
0.569
0.571
0.569
0.569
(ntree = 1000)
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Table 4.5 - Area under curve for GBM model from 10-fold cross-validation
experiments.
Predictor variables include motifs, domains and graphical properties of the
proteins
Gradient Boosting Machine (GBM) - AUC values
(Predictor variables include motifs, domains and graphical properties)
Experiment 1 – Raw input of master dataset with imputed missing values
10-fold CV
0.591
Experiment 2 – [Variable selection with an IV cutoff >= 0.056]
10-fold CV
0.6
Experiment 3 - [Top 3-PCs on all motif/domain information without IV
filtering] + [Topology/Graphical predictors]
10-fold CV
0.584
Table 4.6 – Experiment 2 – Parameter tuning for GBM

1
2
3
4
5
6
7
8

Experiment 2- Variable selection by IV >= 0.056
GBM parameter tuning
Interaction
cv.folds
n.tree shrinkage n.minobsinnode
depth
10
1
5000
0.001
5
10
1
5000
0.001
10
10
1
5000
0.005
1
10
1
5000
0.005
5
10
1
5000
0.005
10
10
1
5000
0.01
1
10
1
5000
0.01
5
10
1
5000
0.01
10

AUC
0.608
0.61
0.6
0.6
0.601
0.597
0.605
0.607
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Table 4.7 - Area under curve for GBM with data segmentation using 10-fold
cross-validation.
Gradient Boosting Machine (GBM) with data segmentation- AUC values
(Predictor variables include motifs, domains and graphical properties)
GBM Segment Experiment 1 - [Variable selection of motif variables
using PCA]. + [Topology/Graphical predictors] :
10-fold CV
0.88
GBM Segment Experiment 2 - [Variable selection of domain variables
using PCA]. + [Topology/Graphical predictors] :
10-fold CV
0.549
GBM Segment Experiment 3 - [Variable selection of motif and
domainvariables using PCA]. + [Topology/Graphical predictors] :
10-fold CV
0.588
Table 4.8 – Overall importance of top 5 variables in predicting proteins
interacting with mutant Htt protein using GBM model.
Predictor Variable
Degree
PC4
Average Shortest Path Length
PC10
PC6

Relative
Influence
12.17
11.70
10.88
9.16
8.98
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Table 4.9 Genes and their encoded proteins containing motifs of importance for GBM Segment Experiment 1
Motif name

MOTIF 153 158 Nuclear
localization signal
MOTIF 686 690 DXDXT
motif
MOTIF 697 701 LXXIL
motif
MOTIF 51 59 Effector
region
MOTIF 51 59 Effector
region
MOTIF 55 65 HIGH region
MOTIF 718 722 KMSKS
region
MOTIF 372 377 Selectivity
filter
MOTIF 493 495 PDZbinding
MOTIF 152 157 Nuclear
localization signal
MOTIF 190 196 Nuclear
localization signal

Mouse
Uniprot
Protein
ID
Q99PI5

Human
Ortholog

Protein Function

LPIN2

nuclear transcriptional coactivator for PPARGC1A to
modulate lipid metabolism
Fatty acid metabolism

P35276
P63011
Q9CZT8

RAB3D
RAB3A
RAB3B

GTPase mediated signal transduction, protein (vesicular)
transport
Exocytosis, regulation of synaptic vesicle fusion,
neurotransmitter release
Protein transport (vesicular traffic of proteins)

Q8BMJ2

LARS

nucleotide binding and aminoacyl-tRNA editing activity

P16388

KCNA1

ion channel activity and potassium channel activity
primarily in the brain

Q61937

NPM1

ribosome biogenesis, centrosome duplication, histone
assembly, cell proliferation, and regulation of tumor
suppressors p53/TP53
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Motif name

MOTIF 235 240 Substrate
recognition
MOTIF 235 240 Substrate
recognition

Mouse
Uniprot
Protein
ID
P48962

Human
Ortholog

Protein Function

SLC25A4

P51881

SLC25A5

Catalyzes the exchange of cytoplasmic ADP with
mitochondrial ATP across the mitochondrial inner
membrane.
Role in chromosome segregation, Catalyzes the exchange
of cytoplasmic ADP with mitochondrial ATP across the
mitochondrial inner membrane.
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Table 4.10 – Overall importance of top 10 variables in predicting proteins
interacting with mutant Htt protein using Lasso Regression model.
Predictor variable
Betweenness Centrality
Closeness Centrality
DOMAIN 36 109 H15
MOTIF 564 578 Bipartite nuclear localization signal
MOTIF 416 421 Nuclear localization signal.
MOTIF 9 15 Nuclear localization signal.
Topological Coefficient
MOTIF 89 95 Required for SUMO paralog-specific binding.
DOMAIN 1 79 Ubiquitin-like.
MOTIF 261 289 Q motif

Overall
importance
55.73068938
3.79704057
0.391185768
0.262330373
0.236135785
0.212858651
0.202029349
0.155780768
0.141763696
0.138626675

Table 4.11 Genes and their encoded proteins containing motifs and domains of importance found using Lasso
regression for Experiment 2.
Motif/Domain
name

Mouse
Uniprot
Protein ID
Q7TMK9

Human
Ortholog

Protein Function

HNRNPQ

MOTIF 416 421
Nuclear localization
signal.
MOTIF 9 15
Nuclear localization
signal.

P14733

LMNB1

RNA binding and splicing, mRNA processing,
Component of the GAIT (gamma interferon-activated
inhibitor of translation) complex, mediates interferongamma-induced translation inhibition in inflammation
processes.
provides a framework for the nuclear envelope,
interacts with chromatin.

O88569

HNRNPA2B1

MOTIF 89 95
Required for SUMO
paralog-specific
binding.
MOTIF 261 289 Q
motif

P57080

USP25

Q61496

DDX4

MOTIF 564 578
Bipartite nuclear
localization signal.

pre-mRNA processing in the nucleus, mRNA
metabolism and transport, involved in chromatin
regulation and acetylation and telomere extension,
protecting telomeric DNA repeat against endonuclease
digestion,
peptidase activity and thiol-dependent ubiquitinspecific protease activity.

nucleic acid binding and ATP-dependent helicase
activity, involved in gene silencing processes by RNA
in mitotic prophase.

124

125

Motif/Domain
name
DOMAIN 36 109
H15
DOMAIN 1 79
Ubiquitin-like

Mouse
Uniprot
Protein ID
P15864
P43274
P43276
P54726
P54728

Human
Ortholog

Protein Function

HIST1H1C
HIST1H1E
HIST1H1B
RAD23A
RAD23B

condensation of nucleosome chains, DNA, RNA and
chromatin binding, DNA methylation, cellular
response to stress, chromatin regulation/acetylation
nucleotide excision repair, and recognition of DNA
repair and DNA damage, delivery of polyubiquitinated
proteins to the proteasome,
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Information Values for Motif and Domain variables
0.2500

0.25

INFORMATION VALUE (IV)

0.2250
0.2000

0.2

0.1750
0.1500

0.15

0.1250
0.1000

0.1

0.0750
0.0500

0.05

0.0250
0

ClosenessCentrality
M.1469
D.5211
D.13145
M.294
D.130
D.9740
D.154
D.171
D.1048
D.1837
D.2320
D.3020
D.3864
D.4798
D.5549
D.6173
D.7240
D.8230
D.9194
D.9693
D.10212
D.10950
D.11689
D.12318
D.12890
D.13773
D.14430
D.15110
D.177
D.2313
D.3471
D.6261
D.8531
D.11155
D.13325
D.15008
M.1355
M.1513

0.0000

VARIABLES

Figure 4.1- Information Value of Motif and domain variables.
The red dotted line (IV = 0.056) represents the cutoff IV selected for model building.
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Figure 4.2 - Full scree plot of variance explained by the top 150 principal components of motif and domain variables.
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Figure 4.3- Receiver Operating Curves (ROC) of data segments for Experiment 2 using Lasso regression
Motif-topology segment (in Red), domain-topology segment (in Green) and motif and domain - topology segment (in
Blue), only topology segment (purple)
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Figure 4.4 - Variable importance of proteins interacting with mutant Htt as shown by the Random Forest.
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Figure 4.5 – Receiver Operating Curves (ROC) for data segments of the master dataset using GBM model.
Motif-topology segment (in Red), domain-topology segment (in Green) and motif and domain - topology segment (in
Blue).

5 Summary
Although extensive studies on Huntington’s disease (HD) have revealed the
complex pathophysiology of this severely crippling disorder, the sequence of
events through which the mutant Huntingtin (mHtt) protein executes its action still
remains elusive. The complexity of the pathophysiology of HD can be attributed to
the tendency of mHtt to abnormally interact with various other proteins that either
do or do not interact with the wild-type Htt protein in normal conditions. The
presence of Htt protein at various subcellular locations and its association with
numerous other protein partners during its normal course of action also complicates
the picture. The phenotype of HD is therefore an outcome of numerous processes
initiated by the mHtt protein along with other proteins that act as either suppressors
or enhancers of the effects of mHtt protein and PolyQ aggregates. To address this
complexity, researchers have detected and analyzed proteins that physically interact
with wild-type and mHtt proteins and have provided valuable information on
various molecular and cellular processes affected in the mutant cells.
We hypothesized that integration of physical and genetic interactors of wild type
and mHtt protein would enable us to predict unknown interactors of Htt protein
using both unsupervised and supervised machine learning approaches. We built a
Huntington’s disease integrome (HDI) integrating human orthologs of protein
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interactors of wild-type and mHtt in a mouse model of HD, with genetic modifiers
of mHtt toxicity found in yeast HD models.
We used an unsupervised machine learning algorithm to partition the network into
clusters and in the process discovered a novel connection linking Huntington’s
disease with chromosome condensation, DNA damage and apoptosis. We
identified 27 candidate genes and validated three (NPLOC4, TUBGCP2 and
NLRC4) of those genes in a drosophila model of HD These findings are novel and
remarkable for Huntington’s disease and help establish our model implicating the
role of mHtt in causing abnormal chromatin condensation, DNA damage, and
neuronal cell death.
We used a separate supervised machine learning approach to create a model that
built on the structural and graphical properties of protein interactors of both wild
and mHtt protein. This model demonstrated that the information contained in
proteins such as their motifs, domains and graphical properties have the ability to
predict an interaction with Huntingtin protein, and offer a way to test and predict
other interactors of wild type and mHtt protein.
Despite extensive research, researchers are still working to close gaps between the
molecular processes affected in HD and their transition to clinical symptoms in HD
patients. We postulated a systems biology approach utilizing machine learning
techniques to reconcile the space between the HD genotype and phenotype. Indeed,
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the machine learning approaches applied here put forth a system to identify
molecular processes yet unknown to be involved in HD, in the hope of developing
curative therapeutic options for this disabling disease.

6 Appendices
6.1 Network Properties of HDI
Given a graph G with vertices {v1, v2, ……, vn}, the adjacency matrix of G is
defined to be as follows:
1 𝑖𝑓 (𝑣𝑖 , 𝑣𝑗 )𝑖𝑠 𝑎𝑛 𝑒𝑑𝑔𝑒 𝑖𝑛 𝐺
𝐴 = (𝑎𝑖𝑗 ) with 𝑎𝑖𝑗 = {
0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
For an unweighted network, the adjacency 𝑎𝑖𝑗 = 1 if the nodes i and j are connected
and 0 otherwise while for a weighted network, 0 ≤ 𝑎𝑖𝑗 ≤ 1.
6.1.1 Network heterogeneity
The connectivity of a node is denoted by the number of its direct neighbors (for
unweighted networks) and by the sum of the strength of its connections to other
nodes (for weighted networks)(Dong and Horvath, 2007)
𝐶𝑜𝑛𝑛𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑖 = 𝑘𝑖 = ∑ 𝑎𝑖𝑗
𝑗 ≠𝑖

Network heterogeneity is the coefficient of variation of the connectivity.(Dong and
Horvath, 2007)

𝐻𝑒𝑡𝑒𝑟𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 =
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√𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 (𝑘)
𝑚𝑒𝑎𝑛 (𝑘)
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A network with high heterogeneity has a tendency to exhibit hubs in its
structure.(Dong and Horvath, 2007)
6.1.2 Average number of neighbors
It denotes the average connectivity of a node in the network.(Assenov et al., 2008)
(See Network density)
6.1.3 Network density
For a given network with n nodes, the connectivity of n, is denoted by kn, which is
a set of numbers of its neighbors. The average number of neighbors of the node n,
indicates its average connectivity (average number of neighbors) in the network.
Network density is a normalized version of the average connectivity(Dong and
Horvath, 2007) and is given by:

𝑁𝑒𝑡𝑤𝑜𝑟𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =

∑𝑖 ∑𝑗≠𝑖 𝛼𝑖𝑗
𝑆1 (𝑘)
𝑚𝑒𝑎𝑛(𝑘)
=
=
𝑛(𝑛 − 1)
𝑛(𝑛 − 1)
𝑛−1

The density of a network lies between 0 and 1; as the value leans towards 1, the
density of edges in the network increases. Network density does not consider
duplicated edges or self-loops.
6.1.4 Network diameter
Network diameter is the largest distance between two nodes in a network.
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6.1.5 Clustering coefficient
The clustering coefficient of a node is ratio N/M, where N is the total number of
edges between the neighbors of n, and M is the total number of edges that can
possibly exist between the neighbors of n. This is represented by the following
equation(Dong and Horvath, 2007):
𝐶𝑙𝑢𝑠𝑡𝑒𝑟𝐶𝑜𝑒𝑓𝑖 =

∑𝑙 ≠𝑖 ∑𝑚≠𝑖,𝑙 𝑎𝑖𝑙 𝑎𝑙𝑚 𝑎𝑚𝑖
(∑𝑙≠𝑖 𝑎𝑖𝑙 )2 − ∑𝑙≠𝑖 𝑎𝑖𝑙2

It can also be defined as (Assenov et al., 2008)
𝐶𝑙𝑢𝑠𝑡𝑒𝑟𝐶𝑜𝑒𝑓𝑖 =

2𝑒𝑖
𝑘𝑖 (𝑘𝑖−1 )

where, 𝑘𝑖 is the number of neighbors of node i, and 𝑒𝑖 is the total number of
connected pairs between all neighbors of node i. The clustering coefficient of a
node always lies between 0 and 1. The network clustering coefficient is the average
of clustering coefficients of all the nodes in the network.
6.1.6 Average shortest path length
It is also known as the characteristic path length. It measures the expected distance
between two connected nodes in a network.(Assenov et al., 2008)
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6.2 Rscripts
To ensure reproducibility of results, Rscripts used for analysis have been
documented in the form of Jupyter notebooks and uploaded on GitHub.
6.2.1 IV calculation and Lasso Regression – Experiment 2
##################################################################
## STEP I - Calculate Information values of variables
## STEP II - Lasso regularization
##################################################################
## Read files
setwd("C:/PhD folder/SVM project/AnalysisOutputs/MLProject_PhaseII")
library(dplyr)
df2 <- read.delim(file = "mergedfiles_all_withNA.txt", header = T, sep = "\t")
df2[1:5, 778:781]
rownames(df2) <- df2$Row.names
predictorX <- df2[,3:781] # identify the columns representing the variables and
convert to matrix.
dim(predictorX)
predictorX[1:5,775:779]
class(predictorX)
### Data prep ######################################################
### STRATEGY - Impute missing values in the data
### Step 1 - Impute missing values in motif-domain segments with -1
### Step 2 - Impute missing values in topology columns with the mean of each
column.
### Step 3 - Find Information Values of the predictor variables
##################################################################
### Imputation of missing values in motif, domain segments with -1
predictorX[,1:769][is.na(predictorX[,1:769])] <- -1 # replace all NA in the
categorical variables (motif and domain) with -1
# Imputation of missing values in topology columns with mean of the column
values.
library (zoo)
predictorX[,770:779] <- na.aggregate(predictorX[,770:779])
sum(is.na(predictorX)) # check ..should be zero
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# Linking the uniprot IDS with their respective group labels.
predictorX$uniprot_swissprot <- row.names(predictorX) # create a column with
uniprot IDs based on the row names.
class(predictorX$uniprot_swissprot) # must be character
dataf <- read.delim(file= "all_uniprotIDs.txt", header = TRUE, sep= "\t") ## Data
frame containing Uniprot Swiss ID
dataf$uniprot_swissprot <- as.character(dataf$uniprot_swissprot) # convert factor
to character.
class(dataf$uniprot_swissprot)# must be "character"
target <- left_join (predictorX,dataf,by="uniprot_swissprot") # this function will
link the unique protein ids with their group labels !!
mytarget <- target[,c(1:780,782)]
mytargetvariable <- mytarget[,781] # the target variable
x = predictorX[1:779] #dataframe of features
y = mytargetvariable #dependent variable
# recreate binary tags
y.wtmt <- ifelse(y %in% c("group2", "group3"), 1, 0)
y.wtOnly <- ifelse(y=="group1", 1, 0)
y.mtOnly <- ifelse(y=="group2", 1, 0)
table(y.wtmt,y)
table(y.wtOnly,y)
table(y.mtOnly,y)
class(y.wtmt); class(y.wtOnly) # both (target variables) have to be numeric
class(x$M.18)
x[,c(1:769)] <- lapply(x[,c(1:769)], factor) # convert independent categorical
variables to factor
#data[cols] <- lapply(data[cols], factor)
x <- cbind(x,y.wtmt); x[1:5,775:780] # bind target variable to the predictor
variables.
##################################################################
# Compute Information value and WOE
# NOTE: The binary target variable is set to "Binding to mutant (mutant only vs.
mutant+WT)"
##################################################################
library (Information) # load library
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library(xlsx)
IV <- create_infotables(data=x, y="y.wtmt", bins=10, parallel=FALSE) # all 554
entries
#summary of IV values of all independent variables
V_Value = data.frame(IV$Summary)
range_V_Value <- range(V_Value$IV)
#write.xlsx(V_Value, file = "IVvalues.xlsx", col.names = TRUE, row.names =
FALSE)
V_Value <- V_Value[order(- V_Value$IV),] # order the IV values in descending
order.
#plot IV values in bar plot
barplot(V_Value$IV[1:157], col = "darkgreen", xlab = "Variables", ylab = "IV
value", names.arg = names(IV$Summary$Variable), main = "Information Value
Summary")
####### Select variables with IV value >= 0.056
V_Value <- subset(V_Value, IV>= 0.056)
# Subset predictorX with the variables with IV >= 0.056
myvec <- as.vector(V_Value$Variable)
predictorX.subset <- predictorX[, myvec]; dim(predictorX.subset) # subset and
check.
# Note: the predictor subset has missing values imputed as -1 for motif domain
variables and mean of
# column values for topology variables.
######################################
###### Logistic Regression on the new subset
######################################
# Input Data prep
# Linking the uniprot IDS with their respective group labels.
predictorX.subset$uniprot_swissprot <- row.names(predictorX.subset) # create a
column with uniprot IDs based on the row names.
class(predictorX.subset$uniprot_swissprot) # must be character
dataf <- read.delim(file= "all_uniprotIDs.txt", header = TRUE, sep= "\t") ## Data
frame containing Uniprot Swiss ID
dataf$uniprot_swissprot <- as.character(dataf$uniprot_swissprot) # convert factor
to character.
class(dataf$uniprot_swissprot)# must be "character"
target <- left_join (predictorX.subset,dataf,by="uniprot_swissprot") # this
function will link the unique protein ids with their group labels !!
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mytarget <- target[,c(1:158,160)]
mytargetvariable <- target[,160] # the target variable
x = predictorX.subset[1:157] #dataframe of features
y = mytargetvariable #dependent variable
# recreate binary tags
y.wtmt <- ifelse(y %in% c("group2", "group3"), 1, 0)
y.wtOnly <- ifelse(y=="group1", 1, 0)
y.mtOnly <- ifelse(y=="group2", 1, 0)
table(y.wtmt,y)
table(y.wtOnly,y)
table(y.mtOnly,y)
# ############### Lasso Group 2 + Group 3##########################
## AUC = 0.652 for IV cutoff >= 0.056
################################################################
library(glmnet) # load library
set.seed(1)
lasso <- glmnet(as.matrix(x), y.wtmt, alpha = 1,family = "binomial")
plot(lasso, label = TRUE)
plot(lasso, xvar = "lambda", label = TRUE)
print(lasso)
set.seed(2)
cvfit_lasso <- cv.glmnet(as.matrix(x),y.wtmt,alpha = 1, family =
"binomial",type.measure = "deviance")
plot(cvfit_lasso)
#lambda minimum of cvfit which gives minimum mean cross-validated error.(kmeans cross validation)
cvfit_lasso$lambda.min
cvfit_lasso$lambda.1se
#coefficients for the lambda minimum (lambda.min) and most regularized
lambda (lambda.1se) values.
coef(cvfit_lasso, s = "lambda.min")
coef(cvfit_lasso, s = "lambda.1se")
## prediction using lambda min for lasso regression
mypc.comp <- as.matrix(x); class(x)
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lasso_pred <- predict(lasso, newx = mypc.comp, type = "response", s =
cvfit_lasso$lambda.min)
lasso_pred
class(y.wtmt)
class(lasso_pred)
## ploting the ROC curve using the above predictions
library(pROC)
lrocobj <- roc(y.wtmt,as.numeric(lasso_pred))
plot.roc(lrocobj, print.auc = TRUE, legacy.axes = TRUE, grid=c(0.1,
0.2),print.thres=TRUE, main = "Lasso ROC - All-in-one| IV>=0.056|group 2 &
3")
# plot.roc(smooth(lrocobj))
auc(lrocobj) # area under curve for lasso ROC
# Variable importance
# use caret package
library(caret)
varimp_lasso <- varImp(lasso, lambda = cvfit_lasso$lambda.min)
# write.xlsx(varimp_lasso,file = "varimp_lasso.xlsx", sheetName =
"Varimp_lasso")
# ##Lasso - 10-fold cv - Grp 2 +Grp 3 ###############################
# ## AUC - 0621 for IV >= 0.056
##############################################################
library(cvTools) #run the above line if you don't have this library
library (glmnet)
k <- 10 #the number of folds
set.seed(123)
folds <- cvFolds(NROW(x), K=k)
x$kfoldlpred <- rep(0,nrow(x))
kfoldprediction <for(i in 1:k){
train <- x[folds$subsets[folds$which != i], -158] #Set the training set
train_response <- y.wtmt[folds$subsets[folds$which != i]] # set the training set
response
validation <- x[folds$subsets[folds$which == i], -158] #Set the validation set
lasso_newglm <- glmnet(as.matrix(train), train_response, alpha = 1,family =
"binomial") #Get your new logistic regression model (just fit on the train data)
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randomseed = 123 + (i-1)*10
set.seed(randomseed)
lasso_cvglm <- cv.glmnet(as.matrix(train), train_response, alpha = 1, family =
"binomial",type.measure = "deviance")
lasso_newpred <- predict(lasso_newglm,newx = as.matrix(validation), type =
"response", s = c(lasso_cvglm$lambda.min)) #Get the predicitons for the
validation set (from the model just fit on the train data)
x[folds$subsets[folds$which == i], ]$kfoldlpred <- lasso_newpred #Put the
hold out prediction in the data set for later use
}
as.data.frame(x$kfoldlpred) # predictions for all proteins using k-fold validation !
(10-fold)
# ROC curve
class(lasso_newpred)
lrocobj1 <- roc(y.wtmt,as.numeric(x$kfoldlpred))
plot.roc(lrocobj1, print.auc = TRUE, legacy.axes = TRUE, grid=c(0.1,
0.2),print.thres=TRUE, main = "Lasso ROC|All-in-one|IV>=0.056\n|kfoldpredictions - group 2 & 3")
# plot.roc(smooth(lrocobj))
auc(lrocobj1) # area under curve for lasso ROC
### END!! DO NOT RUN
##################################################################
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6.2.2 Random forest – Experiment 2
# Identify features and variables.
x = predictorX.subset[1:157] #dataframe of features
y = mytargetvariable #dependent variable
# ## Random Forest ############################################
# ## RF parameters - ntree = 500, mtry = 12
#############################################################
library (cvTools)
k <- 10 #the number of folds
set.seed(123)
folds <- cvFolds(NROW(x), K=k)
x$kfoldlpred0 <- rep(0,nrow(x))
x$kfoldlpred1 <- rep(0,nrow(x))
kfoldprediction <for(i in 1:k){
train <- x[folds$subsets[folds$which != i], c(1:157)] # training set
train_response <- y.wtmt[folds$subsets[folds$which != i]] # training set
response
validation <- x[folds$subsets[folds$which == i], c(1:157)] # validation set
rf_grp1 <- randomForest(as.factor(train_response)~., data = train, importance =
TRUE)# get the RF model (just fit on the train data)
randomseed = 123 + (i-1)*10
set.seed(randomseed)
rf_newpred <- predict(rf_grp1, newdata = validation, type = "prob", norm.votes
= TRUE, predict.all = FALSE) #Get the predicitons for the validation set (from
the model just fit on the train data)
x[folds$subsets[folds$which == i], ]$kfoldlpred0 <- rf_newpred[,1]
x[folds$subsets[folds$which == i], ]$kfoldlpred1 <- rf_newpred[,2]#Put the
hold out prediction in the data set for later use
}
as.data.frame(x[,158:159]) # predictions for all proteins using 10-fold validation
# ROC curve for Random forest 10-fold cv
library(pROC)
rocobj_grp1 <- roc(y.wtmt, x$kfoldlpred1)
plot.roc(rocobj_grp1, print.auc = TRUE, legacy.axes = TRUE, grid=c(0.1,
0.2),main = "Random Forest| 10-fold cv|IV>= 0.056|\nmutant binding
(Grp2+Grp3)|mtry = 12|ntree = 500")

144

6.2.3 Gradient Boosting Machine – Experiment 2
# Identify features and variables.
x = predictorX.subset[1:157] #dataframe of features
y = mytargetvariable #dependent variable
# ## GBM ###################################################
# ## GBM parameters – minobsnode = 10, shrinkage =0.001, ntrees = 5000
#############################################################
library (cvTools)
train <- data.frame(x, y.wtmt)
k <- 10 #the number of folds
set.seed(123)
folds <- cvFolds(NROW(train), K=k)
train$kfoldlpred <- rep(0,nrow(train))
kfoldprediction <for(i in 1:k){
training <- train[folds$subsets[folds$which != i], -159] #Set the training set
training_response <- y.wtmt[folds$subsets[folds$which != i]] # set the training
set response
validation <- train[folds$subsets[folds$which == i], -159] #Set the validation
set
fit.gbm <- gbm(y.wtmt~., data=training, distribution = "bernoulli",
n.trees = 5000,
interaction.depth = 1,
n.minobsinnode = 10,
shrinkage = 0.001,
cv.folds = 10
)
#gbm.perf(fit.gbm)
randomseed = 123 + (i-1)*10
set.seed(randomseed)
gbm_newpred <- predict(fit.gbm, newdata=validation,
gbm.perf(fit.gbm,plot.it=F),type="response") #Get the predicitons for the
validation set (from the model just fit on the train data)
train[folds$subsets[folds$which == i], ]$kfoldlpred <- gbm_newpred #Put the
hold out prediction in the data set for later use
}
as.data.frame(train$kfoldlpred) # predictions for all proteins using 10-fold
validation
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# ROC curve for GBM 10-fold cv
library(pROC)
roc(train$y.wtmt, train$kfoldlpred, plot= TRUE,
legacy.axes = TRUE, grid=c(0.1, 0.2), print.auc = T,
main = "GBM | All-in-one | Binary Target=Mutant (Grp 2+Grp 3) \n| 10-fold
cv | n.minobs = 10, shrinkage = 0.001, ntrees = 5000")
### create a graph with all ROC curves for Exp 2 - Lasso, Random Forest, GBM
roc(train$y.wtmt, train$kfoldlpred, plot= TRUE,
legacy.axes = TRUE, grid=c(0.1, 0.2), print.auc = T,
main = "Experiment 2 | ROC curves\n Lasso, Random Forest and GBM |Binary
Target=Mutant (Grp 2+Grp 3)")
plot.roc(lrocobj1, print.auc = TRUE, add = TRUE, col = "red", legacy.axes =
TRUE, grid=c(0.1, 0.2),print.auc.y = 0.8,print.auc.x = 0.2)
plot.roc(rocobj_grp1, print.auc = TRUE,add = TRUE, col = "green", legacy.axes
= TRUE, grid=c(0.1, 0.2), print.auc.y = 0.6,print.auc.x = 0.4)
legend("bottomright", col = c("black", "red", "green"), legend = c("GBM",
"Lasso", "Random Forest"), lty = 1)
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6.2.4 Gradient Boosting Machine – with Data segmentation
## GBM for Motif-Topology segment
##################################
# Identify features and variables
x = predictorX[1:60] #dataframe of features
y = mytargetvariable #dependent variable
# Creating binary tags
# group 2 and group 3 proteins are tagged with 1 and group 1 proteins with 0
y.wtmt <- ifelse(y %in% c("group2", "group3"), 1, 0)
y.wtOnly <- ifelse(y=="group1", 1, 0)
table(y.wtmt,y)
table(y.wtOnly,y)
train5 <- data.frame(y.wtmt, x)
# .. PCA analysis to reduce motif variables
pc.motif <- prcomp(train5[,12:61])
summary(pc.motif)
plot(pc.motif, type='l') # .. scree plot
# check R's PCA list object
names(pc.motif)
# variable loadings: projections of the original variable onto the PC-space
head(pc.motif$rotation)
head(pc.motif$x)
# variance explained by top PCs
plot(pc.motif$sdev/sum(pc.motif$sdev)*100) # .. full scree plot
# keep only top 12 PCs
pcs <- pc.motif$x
pcs12 <- pcs[,1:12]
##############################################################
Repeated 10-fold cross validation - Motif- Topology Segment
# AUC 0.88 for nsim = 1
# AUC - 0.86 for nsim = 100
##############################################################
library (gbm)
library(cvTools)
library(ROCR)
library(pROC)
library(xlsx)
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# create empty roc plot to plot roc curves
plot.roc(0:1, 0:1, type = "n", legacy.axes = TRUE, main = "GBM | Binary
Target=MT binding with PCA | repeated 10-Fold CV")
k <- 10 #the number of folds
x = cbind(predictorX[1:10], pcs12)
y <- y.wtmt
set.seed(1234)
folds <- cvFolds(NROW(x), K=k)
nsim <- 1 # number of repetitions
myauc <- rep(0, nsim)
mypreds <- data.frame(matrix(0, nrow(x),ncol = 100)) # create a dataframe to
store results of all 100 nsim repetitions
row.names(mypreds) <- row.names(x) # row names for the dataframe
names(mypreds) <- paste("K", (1:100), sep = "") # column names
j <- 1
x$kfoldlpred <- rep(0,nrow(x)) # append a column to original dataframe to
temporarily store results of each k-fold
ptm <- proc.time()
repeatcv <- function(){
while (j <= nsim){
for(i in 1:k){
train <- x[folds$subsets[folds$which != i], -23] #Set the training set
train_response <- y[folds$subsets[folds$which != i]] # set the training set
response
validation <- x[folds$subsets[folds$which == i], -23] #Set the validation set
randomseed = 7842 + (i-1)*10 +j
set.seed(randomseed)
new_gbm.fit <- gbm(train_response~., data=train, distribution = "bernoulli",
n.trees = 5000,
interaction.depth = 1,
n.minobsinnode = 1,
shrinkage = 0.001,
cv.folds = 10)
new_gbmpred <- predict(new_gbm.fit, newdata=validation,
gbm.perf(new_gbm.fit,plot.it=F),
type="response")
x[folds$subsets[folds$which == i],]$kfoldlpred <- new_gbmpred
}
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mypreds[,j] <- x$kfoldlpred
rocobj2 <- roc(y.wtmt, as.numeric(mypreds[,j]))
myauc[j] <- rocobj2$auc # assign auc value to the jth item of your numeric
vector 'myauc'
plot.roc(rocobj2,add = TRUE)
j <- j+1
}
predictions <- as.data.frame(mypreds[,1],row.names = row.names(mypreds))
write.xlsx(predictions, file = "predictions_gbmmotiftop.xlsx", col.names =
TRUE, row.names = TRUE)
returnlist = list(predictions,myauc,mean(myauc), sd(myauc))
returnlist
roc(train5$y.wtmt, mypreds[,1], plot= TRUE,legacy.axes = TRUE, grid=c(0.1,
0.2), print.auc = T, main = "GBM|Motif-Top with PCA| Binary Target =
Mutant(Grp2+Grp3)")
}
repeatcv()
proc.time() – ptm
# create ROC chart for motif-topology segment
gbm_motiftop <- read.xlsx(file = "predictions_gbmmotiftop.xlsx", sheetIndex =
1, sheetName = "Sheet1")
roc(train5$y.wtmt, gbm_motiftop$mypreds...1., plot = TRUE, col = "red",
legacy.axes = TRUE, grid=c(0.1, 0.2),print.auc = TRUE, print.auc.y =
0.2,print.auc.x = 0.75, main = "GBM ROC| Data segmentation with PCA|\nBinary
Target = Mutant (Grp 2 & 3)")
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